{
  "list": [
    {
      "PRODUCTID": "0002-0213_458ef2aa-cd5f-48bc-8829-82420cfed33b",
      "PRODUCTNDC": "0002-0213",
      "PRODUCTTYPENAME": "HUMAN OTC DRUG",
      "PROPRIETARYNAME": "Humulin",
      "PROPRIETARYNAMESUFFIX": "R",
      "NONPROPRIETARYNAME": "Insulin human",
      "DOSAGEFORMNAME": "INJECTION, SOLUTION",
      "ROUTENAME": "PARENTERAL",
      "STARTMARKETINGDATE": 19830627,
      "ENDMARKETINGDATE": "",
      "MARKETINGCATEGORYNAME": "BLA",
      "APPLICATIONNUMBER": "BLA018780",
      "LABELERNAME": "Eli Lilly and Company",
      "SUBSTANCENAME": "INSULIN HUMAN",
      "ACTIVE_NUMERATOR_STRENGTH": 100,
      "ACTIVE_INGRED_UNIT": "[iU]/mL",
      "PHARM_CLASSES": "Insulin [CS], Insulin [EPC]",
      "DEASCHEDULE": "",
      "NDC_EXCLUDE_FLAG": "N",
      "LISTING_RECORD_CERTIFIED_THROUGH": 20241231
    },
    {
      "PRODUCTID": "0002-0800_dec32ead-837e-4331-ab55-f3bbccea5b38",
      "PRODUCTNDC": "0002-0800",
      "PRODUCTTYPENAME": "HUMAN OTC DRUG",
      "PROPRIETARYNAME": "Sterile Diluent",
      "PROPRIETARYNAMESUFFIX": "",
      "NONPROPRIETARYNAME": "diluent",
      "DOSAGEFORMNAME": "INJECTION, SOLUTION",
      "ROUTENAME": "SUBCUTANEOUS",
      "STARTMARKETINGDATE": 19870710,
      "ENDMARKETINGDATE": "",
      "MARKETINGCATEGORYNAME": "BLA",
      "APPLICATIONNUMBER": "BLA018781",
      "LABELERNAME": "Eli Lilly and Company",
      "SUBSTANCENAME": "WATER",
      "ACTIVE_NUMERATOR_STRENGTH": 1,
      "ACTIVE_INGRED_UNIT": "mL/mL",
      "PHARM_CLASSES": "",
      "DEASCHEDULE": "",
      "NDC_EXCLUDE_FLAG": "N",
      "LISTING_RECORD_CERTIFIED_THROUGH": 20241231
    },
    {
      "PRODUCTID": "0002-1152_b597917f-9673-4331-809d-79a538bb943c",
      "PRODUCTNDC": "0002-1152",
      "PRODUCTTYPENAME": "HUMAN PRESCRIPTION DRUG",
      "PROPRIETARYNAME": "MOUNJARO",
      "PROPRIETARYNAMESUFFIX": "",
      "NONPROPRIETARYNAME": "tirzepatide",
      "DOSAGEFORMNAME": "INJECTION, SOLUTION",
      "ROUTENAME": "SUBCUTANEOUS",
      "STARTMARKETINGDATE": 20230728,
      "ENDMARKETINGDATE": "",
      "MARKETINGCATEGORYNAME": "NDA",
      "APPLICATIONNUMBER": "NDA215866",
      "LABELERNAME": "Eli Lilly and Company",
      "SUBSTANCENAME": "TIRZEPATIDE",
      "ACTIVE_NUMERATOR_STRENGTH": 2.5,
      "ACTIVE_INGRED_UNIT": "mg/.5mL",
      "PHARM_CLASSES": "G-Protein-linked Receptor Interactions [MoA], GLP-1 Receptor Agonist [EPC], Glucagon-like Peptide-1 (GLP-1) Agonists [MoA], Glucose-dependent Insulinotropic Polypeptide Receptor Agonist [EPC]",
      "DEASCHEDULE": "",
      "NDC_EXCLUDE_FLAG": "N",
      "LISTING_RECORD_CERTIFIED_THROUGH": 20241231
    },
    {
      "PRODUCTID": "0002-1200_c2f899b5-287a-4002-ae37-f69418174eb4",
      "PRODUCTNDC": "0002-1200",
      "PRODUCTTYPENAME": "HUMAN PRESCRIPTION DRUG",
      "PROPRIETARYNAME": "Amyvid",
      "PROPRIETARYNAMESUFFIX": "",
      "NONPROPRIETARYNAME": "Florbetapir F 18",
      "DOSAGEFORMNAME": "INJECTION, SOLUTION",
      "ROUTENAME": "INTRAVENOUS",
      "STARTMARKETINGDATE": 20120601,
      "ENDMARKETINGDATE": "",
      "MARKETINGCATEGORYNAME": "NDA",
      "APPLICATIONNUMBER": "NDA202008",
      "LABELERNAME": "Eli Lilly and Company",
      "SUBSTANCENAME": "FLORBETAPIR F-18",
      "ACTIVE_NUMERATOR_STRENGTH": 51,
      "ACTIVE_INGRED_UNIT": "mCi/mL",
      "PHARM_CLASSES": "Positron Emitting Activity [MoA], Radioactive Diagnostic Agent [EPC]",
      "DEASCHEDULE": "",
      "NDC_EXCLUDE_FLAG": "N",
      "LISTING_RECORD_CERTIFIED_THROUGH": 20241231
    },
    {
      "PRODUCTID": "0002-1220_e82b7e9c-6569-415d-9498-084612225c12",
      "PRODUCTNDC": "0002-1220",
      "PRODUCTTYPENAME": "HUMAN PRESCRIPTION DRUG",
      "PROPRIETARYNAME": "TAUVID",
      "PROPRIETARYNAMESUFFIX": "",
      "NONPROPRIETARYNAME": "Flortaucipir F-18",
      "DOSAGEFORMNAME": "INJECTION, SOLUTION",
      "ROUTENAME": "INTRAVENOUS",
      "STARTMARKETINGDATE": 20220701,
      "ENDMARKETINGDATE": "",
      "MARKETINGCATEGORYNAME": "NDA",
      "APPLICATIONNUMBER": "NDA212123",
      "LABELERNAME": "Eli Lilly and Company",
      "SUBSTANCENAME": "FLORTAUCIPIR F-18",
      "ACTIVE_NUMERATOR_STRENGTH": 100,
      "ACTIVE_INGRED_UNIT": "mCi/mL",
      "PHARM_CLASSES": "",
      "DEASCHEDULE": "",
      "NDC_EXCLUDE_FLAG": "N",
      "LISTING_RECORD_CERTIFIED_THROUGH": 20241231
    },
    {
      "PRODUCTID": "0002-1243_b597917f-9673-4331-809d-79a538bb943c",
      "PRODUCTNDC": "0002-1243",
      "PRODUCTTYPENAME": "HUMAN PRESCRIPTION DRUG",
      "PROPRIETARYNAME": "MOUNJARO",
      "PROPRIETARYNAMESUFFIX": "",
      "NONPROPRIETARYNAME": "tirzepatide",
      "DOSAGEFORMNAME": "INJECTION, SOLUTION",
      "ROUTENAME": "SUBCUTANEOUS",
      "STARTMARKETINGDATE": 20230728,
      "ENDMARKETINGDATE": "",
      "MARKETINGCATEGORYNAME": "NDA",
      "APPLICATIONNUMBER": "NDA215866",
      "LABELERNAME": "Eli Lilly and Company",
      "SUBSTANCENAME": "TIRZEPATIDE",
      "ACTIVE_NUMERATOR_STRENGTH": 5,
      "ACTIVE_INGRED_UNIT": "mg/.5mL",
      "PHARM_CLASSES": "G-Protein-linked Receptor Interactions [MoA], GLP-1 Receptor Agonist [EPC], Glucagon-like Peptide-1 (GLP-1) Agonists [MoA], Glucose-dependent Insulinotropic Polypeptide Receptor Agonist [EPC]",
      "DEASCHEDULE": "",
      "NDC_EXCLUDE_FLAG": "N",
      "LISTING_RECORD_CERTIFIED_THROUGH": 20241231
    },
    {
      "PRODUCTID": "0002-1433_d89b25b3-0f8d-4cbd-b58b-44d112cd7fe6",
      "PRODUCTNDC": "0002-1433",
      "PRODUCTTYPENAME": "HUMAN PRESCRIPTION DRUG",
      "PROPRIETARYNAME": "Trulicity",
      "PROPRIETARYNAMESUFFIX": "",
      "NONPROPRIETARYNAME": "Dulaglutide",
      "DOSAGEFORMNAME": "INJECTION, SOLUTION",
      "ROUTENAME": "SUBCUTANEOUS",
      "STARTMARKETINGDATE": 20140918,
      "ENDMARKETINGDATE": "",
      "MARKETINGCATEGORYNAME": "BLA",
      "APPLICATIONNUMBER": "BLA125469",
      "LABELERNAME": "Eli Lilly and Company",
      "SUBSTANCENAME": "DULAGLUTIDE",
      "ACTIVE_NUMERATOR_STRENGTH": 0.75,
      "ACTIVE_INGRED_UNIT": "mg/.5mL",
      "PHARM_CLASSES": "GLP-1 Receptor Agonist [EPC], Glucagon-Like Peptide 1 [CS], Glucagon-like Peptide-1 (GLP-1) Agonists [MoA]",
      "DEASCHEDULE": "",
      "NDC_EXCLUDE_FLAG": "N",
      "LISTING_RECORD_CERTIFIED_THROUGH": 20241231
    },
    {
      "PRODUCTID": "0002-1434_d89b25b3-0f8d-4cbd-b58b-44d112cd7fe6",
      "PRODUCTNDC": "0002-1434",
      "PRODUCTTYPENAME": "HUMAN PRESCRIPTION DRUG",
      "PROPRIETARYNAME": "Trulicity",
      "PROPRIETARYNAMESUFFIX": "",
      "NONPROPRIETARYNAME": "Dulaglutide",
      "DOSAGEFORMNAME": "INJECTION, SOLUTION",
      "ROUTENAME": "SUBCUTANEOUS",
      "STARTMARKETINGDATE": 20140918,
      "ENDMARKETINGDATE": "",
      "MARKETINGCATEGORYNAME": "BLA",
      "APPLICATIONNUMBER": "BLA125469",
      "LABELERNAME": "Eli Lilly and Company",
      "SUBSTANCENAME": "DULAGLUTIDE",
      "ACTIVE_NUMERATOR_STRENGTH": 1.5,
      "ACTIVE_INGRED_UNIT": "mg/.5mL",
      "PHARM_CLASSES": "GLP-1 Receptor Agonist [EPC], Glucagon-Like Peptide 1 [CS], Glucagon-like Peptide-1 (GLP-1) Agonists [MoA]",
      "DEASCHEDULE": "",
      "NDC_EXCLUDE_FLAG": "N",
      "LISTING_RECORD_CERTIFIED_THROUGH": 20241231
    },
    {
      "PRODUCTID": "0002-1436_bec46346-20b5-4dbe-bac3-b8564e906941",
      "PRODUCTNDC": "0002-1436",
      "PRODUCTTYPENAME": "HUMAN PRESCRIPTION DRUG",
      "PROPRIETARYNAME": "EMGALITY",
      "PROPRIETARYNAMESUFFIX": "",
      "NONPROPRIETARYNAME": "galcanezumab-gnlm",
      "DOSAGEFORMNAME": "INJECTION, SOLUTION",
      "ROUTENAME": "SUBCUTANEOUS",
      "STARTMARKETINGDATE": 20180927,
      "ENDMARKETINGDATE": "",
      "MARKETINGCATEGORYNAME": "BLA",
      "APPLICATIONNUMBER": "BLA761063",
      "LABELERNAME": "Eli Lilly and Company",
      "SUBSTANCENAME": "GALCANEZUMAB",
      "ACTIVE_NUMERATOR_STRENGTH": 120,
      "ACTIVE_INGRED_UNIT": "mg/mL",
      "PHARM_CLASSES": "",
      "DEASCHEDULE": "",
      "NDC_EXCLUDE_FLAG": "N",
      "LISTING_RECORD_CERTIFIED_THROUGH": 20231231
    },
    {
      "PRODUCTID": "0002-1445_39e9a0c8-fced-467c-a773-4c07d7ba060c",
      "PRODUCTNDC": "0002-1445",
      "PRODUCTTYPENAME": "HUMAN PRESCRIPTION DRUG",
      "PROPRIETARYNAME": "TALTZ",
      "PROPRIETARYNAMESUFFIX": "",
      "NONPROPRIETARYNAME": "ixekizumab",
      "DOSAGEFORMNAME": "INJECTION, SOLUTION",
      "ROUTENAME": "SUBCUTANEOUS",
      "STARTMARKETINGDATE": 20160322,
      "ENDMARKETINGDATE": "",
      "MARKETINGCATEGORYNAME": "BLA",
      "APPLICATIONNUMBER": "BLA125521",
      "LABELERNAME": "Eli Lilly and Company",
      "SUBSTANCENAME": "IXEKIZUMAB",
      "ACTIVE_NUMERATOR_STRENGTH": 80,
      "ACTIVE_INGRED_UNIT": "mg/mL",
      "PHARM_CLASSES": "Interleukin-17A Antagonist [EPC], Interleukin-17A Antagonists [MoA]",
      "DEASCHEDULE": "",
      "NDC_EXCLUDE_FLAG": "N",
      "LISTING_RECORD_CERTIFIED_THROUGH": 20231231
    },
    {
      "PRODUCTID": "0002-1457_b597917f-9673-4331-809d-79a538bb943c",
      "PRODUCTNDC": "0002-1457",
      "PRODUCTTYPENAME": "HUMAN PRESCRIPTION DRUG",
      "PROPRIETARYNAME": "MOUNJARO",
      "PROPRIETARYNAMESUFFIX": "",
      "NONPROPRIETARYNAME": "tirzepatide",
      "DOSAGEFORMNAME": "INJECTION, SOLUTION",
      "ROUTENAME": "SUBCUTANEOUS",
      "STARTMARKETINGDATE": 20220513,
      "ENDMARKETINGDATE": "",
      "MARKETINGCATEGORYNAME": "NDA",
      "APPLICATIONNUMBER": "NDA215866",
      "LABELERNAME": "Eli Lilly and Company",
      "SUBSTANCENAME": "TIRZEPATIDE",
      "ACTIVE_NUMERATOR_STRENGTH": 15,
      "ACTIVE_INGRED_UNIT": "mg/.5mL",
      "PHARM_CLASSES": "G-Protein-linked Receptor Interactions [MoA], GLP-1 Receptor Agonist [EPC], Glucagon-like Peptide-1 (GLP-1) Agonists [MoA], Glucose-dependent Insulinotropic Polypeptide Receptor Agonist [EPC]",
      "DEASCHEDULE": "",
      "NDC_EXCLUDE_FLAG": "N",
      "LISTING_RECORD_CERTIFIED_THROUGH": 20241231
    },
    {
      "PRODUCTID": "0002-1460_b597917f-9673-4331-809d-79a538bb943c",
      "PRODUCTNDC": "0002-1460",
      "PRODUCTTYPENAME": "HUMAN PRESCRIPTION DRUG",
      "PROPRIETARYNAME": "MOUNJARO",
      "PROPRIETARYNAMESUFFIX": "",
      "NONPROPRIETARYNAME": "tirzepatide",
      "DOSAGEFORMNAME": "INJECTION, SOLUTION",
      "ROUTENAME": "SUBCUTANEOUS",
      "STARTMARKETINGDATE": 20220513,
      "ENDMARKETINGDATE": "",
      "MARKETINGCATEGORYNAME": "NDA",
      "APPLICATIONNUMBER": "NDA215866",
      "LABELERNAME": "Eli Lilly and Company",
      "SUBSTANCENAME": "TIRZEPATIDE",
      "ACTIVE_NUMERATOR_STRENGTH": 12.5,
      "ACTIVE_INGRED_UNIT": "mg/.5mL",
      "PHARM_CLASSES": "G-Protein-linked Receptor Interactions [MoA], GLP-1 Receptor Agonist [EPC], Glucagon-like Peptide-1 (GLP-1) Agonists [MoA], Glucose-dependent Insulinotropic Polypeptide Receptor Agonist [EPC]",
      "DEASCHEDULE": "",
      "NDC_EXCLUDE_FLAG": "N",
      "LISTING_RECORD_CERTIFIED_THROUGH": 20241231
    },
    {
      "PRODUCTID": "0002-1471_b597917f-9673-4331-809d-79a538bb943c",
      "PRODUCTNDC": "0002-1471",
      "PRODUCTTYPENAME": "HUMAN PRESCRIPTION DRUG",
      "PROPRIETARYNAME": "MOUNJARO",
      "PROPRIETARYNAMESUFFIX": "",
      "NONPROPRIETARYNAME": "tirzepatide",
      "DOSAGEFORMNAME": "INJECTION, SOLUTION",
      "ROUTENAME": "SUBCUTANEOUS",
      "STARTMARKETINGDATE": 20220513,
      "ENDMARKETINGDATE": "",
      "MARKETINGCATEGORYNAME": "NDA",
      "APPLICATIONNUMBER": "NDA215866",
      "LABELERNAME": "Eli Lilly and Company",
      "SUBSTANCENAME": "TIRZEPATIDE",
      "ACTIVE_NUMERATOR_STRENGTH": 10,
      "ACTIVE_INGRED_UNIT": "mg/.5mL",
      "PHARM_CLASSES": "G-Protein-linked Receptor Interactions [MoA], GLP-1 Receptor Agonist [EPC], Glucagon-like Peptide-1 (GLP-1) Agonists [MoA], Glucose-dependent Insulinotropic Polypeptide Receptor Agonist [EPC]",
      "DEASCHEDULE": "",
      "NDC_EXCLUDE_FLAG": "N",
      "LISTING_RECORD_CERTIFIED_THROUGH": 20241231
    },
    {
      "PRODUCTID": "0002-1484_b597917f-9673-4331-809d-79a538bb943c",
      "PRODUCTNDC": "0002-1484",
      "PRODUCTTYPENAME": "HUMAN PRESCRIPTION DRUG",
      "PROPRIETARYNAME": "MOUNJARO",
      "PROPRIETARYNAMESUFFIX": "",
      "NONPROPRIETARYNAME": "tirzepatide",
      "DOSAGEFORMNAME": "INJECTION, SOLUTION",
      "ROUTENAME": "SUBCUTANEOUS",
      "STARTMARKETINGDATE": 20220513,
      "ENDMARKETINGDATE": "",
      "MARKETINGCATEGORYNAME": "NDA",
      "APPLICATIONNUMBER": "NDA215866",
      "LABELERNAME": "Eli Lilly and Company",
      "SUBSTANCENAME": "TIRZEPATIDE",
      "ACTIVE_NUMERATOR_STRENGTH": 7.5,
      "ACTIVE_INGRED_UNIT": "mg/.5mL",
      "PHARM_CLASSES": "G-Protein-linked Receptor Interactions [MoA], GLP-1 Receptor Agonist [EPC], Glucagon-like Peptide-1 (GLP-1) Agonists [MoA], Glucose-dependent Insulinotropic Polypeptide Receptor Agonist [EPC]",
      "DEASCHEDULE": "",
      "NDC_EXCLUDE_FLAG": "N",
      "LISTING_RECORD_CERTIFIED_THROUGH": 20241231
    },
    {
      "PRODUCTID": "0002-1495_b597917f-9673-4331-809d-79a538bb943c",
      "PRODUCTNDC": "0002-1495",
      "PRODUCTTYPENAME": "HUMAN PRESCRIPTION DRUG",
      "PROPRIETARYNAME": "MOUNJARO",
      "PROPRIETARYNAMESUFFIX": "",
      "NONPROPRIETARYNAME": "tirzepatide",
      "DOSAGEFORMNAME": "INJECTION, SOLUTION",
      "ROUTENAME": "SUBCUTANEOUS",
      "STARTMARKETINGDATE": 20220513,
      "ENDMARKETINGDATE": "",
      "MARKETINGCATEGORYNAME": "NDA",
      "APPLICATIONNUMBER": "NDA215866",
      "LABELERNAME": "Eli Lilly and Company",
      "SUBSTANCENAME": "TIRZEPATIDE",
      "ACTIVE_NUMERATOR_STRENGTH": 5,
      "ACTIVE_INGRED_UNIT": "mg/.5mL",
      "PHARM_CLASSES": "G-Protein-linked Receptor Interactions [MoA], GLP-1 Receptor Agonist [EPC], Glucagon-like Peptide-1 (GLP-1) Agonists [MoA], Glucose-dependent Insulinotropic Polypeptide Receptor Agonist [EPC]",
      "DEASCHEDULE": "",
      "NDC_EXCLUDE_FLAG": "N",
      "LISTING_RECORD_CERTIFIED_THROUGH": 20241231
    },
    {
      "PRODUCTID": "0002-1506_b597917f-9673-4331-809d-79a538bb943c",
      "PRODUCTNDC": "0002-1506",
      "PRODUCTTYPENAME": "HUMAN PRESCRIPTION DRUG",
      "PROPRIETARYNAME": "MOUNJARO",
      "PROPRIETARYNAMESUFFIX": "",
      "NONPROPRIETARYNAME": "tirzepatide",
      "DOSAGEFORMNAME": "INJECTION, SOLUTION",
      "ROUTENAME": "SUBCUTANEOUS",
      "STARTMARKETINGDATE": 20220513,
      "ENDMARKETINGDATE": "",
      "MARKETINGCATEGORYNAME": "NDA",
      "APPLICATIONNUMBER": "NDA215866",
      "LABELERNAME": "Eli Lilly and Company",
      "SUBSTANCENAME": "TIRZEPATIDE",
      "ACTIVE_NUMERATOR_STRENGTH": 2.5,
      "ACTIVE_INGRED_UNIT": "mg/.5mL",
      "PHARM_CLASSES": "G-Protein-linked Receptor Interactions [MoA], GLP-1 Receptor Agonist [EPC], Glucagon-like Peptide-1 (GLP-1) Agonists [MoA], Glucose-dependent Insulinotropic Polypeptide Receptor Agonist [EPC]",
      "DEASCHEDULE": "",
      "NDC_EXCLUDE_FLAG": "N",
      "LISTING_RECORD_CERTIFIED_THROUGH": 20241231
    },
    {
      "PRODUCTID": "0002-2214_b597917f-9673-4331-809d-79a538bb943c",
      "PRODUCTNDC": "0002-2214",
      "PRODUCTTYPENAME": "HUMAN PRESCRIPTION DRUG",
      "PROPRIETARYNAME": "MOUNJARO",
      "PROPRIETARYNAMESUFFIX": "",
      "NONPROPRIETARYNAME": "tirzepatide",
      "DOSAGEFORMNAME": "INJECTION, SOLUTION",
      "ROUTENAME": "SUBCUTANEOUS",
      "STARTMARKETINGDATE": 20230728,
      "ENDMARKETINGDATE": "",
      "MARKETINGCATEGORYNAME": "NDA",
      "APPLICATIONNUMBER": "NDA215866",
      "LABELERNAME": "Eli Lilly and Company",
      "SUBSTANCENAME": "TIRZEPATIDE",
      "ACTIVE_NUMERATOR_STRENGTH": 7.5,
      "ACTIVE_INGRED_UNIT": "mg/.5mL",
      "PHARM_CLASSES": "G-Protein-linked Receptor Interactions [MoA], GLP-1 Receptor Agonist [EPC], Glucagon-like Peptide-1 (GLP-1) Agonists [MoA], Glucose-dependent Insulinotropic Polypeptide Receptor Agonist [EPC]",
      "DEASCHEDULE": "",
      "NDC_EXCLUDE_FLAG": "N",
      "LISTING_RECORD_CERTIFIED_THROUGH": 20241231
    },
    {
      "PRODUCTID": "0002-2236_d89b25b3-0f8d-4cbd-b58b-44d112cd7fe6",
      "PRODUCTNDC": "0002-2236",
      "PRODUCTTYPENAME": "HUMAN PRESCRIPTION DRUG",
      "PROPRIETARYNAME": "Trulicity",
      "PROPRIETARYNAMESUFFIX": "",
      "NONPROPRIETARYNAME": "Dulaglutide",
      "DOSAGEFORMNAME": "INJECTION, SOLUTION",
      "ROUTENAME": "SUBCUTANEOUS",
      "STARTMARKETINGDATE": 20200903,
      "ENDMARKETINGDATE": "",
      "MARKETINGCATEGORYNAME": "BLA",
      "APPLICATIONNUMBER": "BLA125469",
      "LABELERNAME": "Eli Lilly and Company",
      "SUBSTANCENAME": "DULAGLUTIDE",
      "ACTIVE_NUMERATOR_STRENGTH": 3,
      "ACTIVE_INGRED_UNIT": "mg/.5mL",
      "PHARM_CLASSES": "GLP-1 Receptor Agonist [EPC], Glucagon-Like Peptide 1 [CS], Glucagon-like Peptide-1 (GLP-1) Agonists [MoA]",
      "DEASCHEDULE": "",
      "NDC_EXCLUDE_FLAG": "N",
      "LISTING_RECORD_CERTIFIED_THROUGH": 20241231
    },
    {
      "PRODUCTID": "0002-2340_b597917f-9673-4331-809d-79a538bb943c",
      "PRODUCTNDC": "0002-2340",
      "PRODUCTTYPENAME": "HUMAN PRESCRIPTION DRUG",
      "PROPRIETARYNAME": "MOUNJARO",
      "PROPRIETARYNAMESUFFIX": "",
      "NONPROPRIETARYNAME": "tirzepatide",
      "DOSAGEFORMNAME": "INJECTION, SOLUTION",
      "ROUTENAME": "SUBCUTANEOUS",
      "STARTMARKETINGDATE": 20230728,
      "ENDMARKETINGDATE": "",
      "MARKETINGCATEGORYNAME": "NDA",
      "APPLICATIONNUMBER": "NDA215866",
      "LABELERNAME": "Eli Lilly and Company",
      "SUBSTANCENAME": "TIRZEPATIDE",
      "ACTIVE_NUMERATOR_STRENGTH": 10,
      "ACTIVE_INGRED_UNIT": "mg/.5mL",
      "PHARM_CLASSES": "G-Protein-linked Receptor Interactions [MoA], GLP-1 Receptor Agonist [EPC], Glucagon-like Peptide-1 (GLP-1) Agonists [MoA], Glucose-dependent Insulinotropic Polypeptide Receptor Agonist [EPC]",
      "DEASCHEDULE": "",
      "NDC_EXCLUDE_FLAG": "N",
      "LISTING_RECORD_CERTIFIED_THROUGH": 20241231
    },
    {
      "PRODUCTID": "0002-2377_bec46346-20b5-4dbe-bac3-b8564e906941",
      "PRODUCTNDC": "0002-2377",
      "PRODUCTTYPENAME": "HUMAN PRESCRIPTION DRUG",
      "PROPRIETARYNAME": "EMGALITY",
      "PROPRIETARYNAMESUFFIX": "",
      "NONPROPRIETARYNAME": "galcanezumab-gnlm",
      "DOSAGEFORMNAME": "INJECTION, SOLUTION",
      "ROUTENAME": "SUBCUTANEOUS",
      "STARTMARKETINGDATE": 20180927,
      "ENDMARKETINGDATE": "",
      "MARKETINGCATEGORYNAME": "BLA",
      "APPLICATIONNUMBER": "BLA761063",
      "LABELERNAME": "Eli Lilly and Company",
      "SUBSTANCENAME": "GALCANEZUMAB",
      "ACTIVE_NUMERATOR_STRENGTH": 120,
      "ACTIVE_INGRED_UNIT": "mg/mL",
      "PHARM_CLASSES": "",
      "DEASCHEDULE": "",
      "NDC_EXCLUDE_FLAG": "N",
      "LISTING_RECORD_CERTIFIED_THROUGH": 20231231
    },
    {
      "PRODUCTID": "0002-2423_b597917f-9673-4331-809d-79a538bb943c",
      "PRODUCTNDC": "0002-2423",
      "PRODUCTTYPENAME": "HUMAN PRESCRIPTION DRUG",
      "PROPRIETARYNAME": "MOUNJARO",
      "PROPRIETARYNAMESUFFIX": "",
      "NONPROPRIETARYNAME": "tirzepatide",
      "DOSAGEFORMNAME": "INJECTION, SOLUTION",
      "ROUTENAME": "SUBCUTANEOUS",
      "STARTMARKETINGDATE": 20230728,
      "ENDMARKETINGDATE": "",
      "MARKETINGCATEGORYNAME": "NDA",
      "APPLICATIONNUMBER": "NDA215866",
      "LABELERNAME": "Eli Lilly and Company",
      "SUBSTANCENAME": "TIRZEPATIDE",
      "ACTIVE_NUMERATOR_STRENGTH": 12.5,
      "ACTIVE_INGRED_UNIT": "mg/.5mL",
      "PHARM_CLASSES": "G-Protein-linked Receptor Interactions [MoA], GLP-1 Receptor Agonist [EPC], Glucagon-like Peptide-1 (GLP-1) Agonists [MoA], Glucose-dependent Insulinotropic Polypeptide Receptor Agonist [EPC]",
      "DEASCHEDULE": "",
      "NDC_EXCLUDE_FLAG": "N",
      "LISTING_RECORD_CERTIFIED_THROUGH": 20241231
    },
    {
      "PRODUCTID": "0002-2457_dcabc03d-6a72-467a-8043-9eb12ce9c856",
      "PRODUCTNDC": "0002-2457",
      "PRODUCTTYPENAME": "HUMAN PRESCRIPTION DRUG",
      "PROPRIETARYNAME": "ZEPBOUND",
      "PROPRIETARYNAMESUFFIX": "",
      "NONPROPRIETARYNAME": "tirzepatide",
      "DOSAGEFORMNAME": "INJECTION, SOLUTION",
      "ROUTENAME": "SUBCUTANEOUS",
      "STARTMARKETINGDATE": 20231108,
      "ENDMARKETINGDATE": "",
      "MARKETINGCATEGORYNAME": "NDA",
      "APPLICATIONNUMBER": "NDA217806",
      "LABELERNAME": "Eli Lilly and Company",
      "SUBSTANCENAME": "TIRZEPATIDE",
      "ACTIVE_NUMERATOR_STRENGTH": 15,
      "ACTIVE_INGRED_UNIT": "mg/.5mL",
      "PHARM_CLASSES": "G-Protein-linked Receptor Interactions [MoA], GLP-1 Receptor Agonist [EPC], Glucagon-like Peptide-1 (GLP-1) Agonists [MoA], Glucose-dependent Insulinotropic Polypeptide Receptor Agonist [EPC]",
      "DEASCHEDULE": "",
      "NDC_EXCLUDE_FLAG": "N",
      "LISTING_RECORD_CERTIFIED_THROUGH": 20241231
    },
    {
      "PRODUCTID": "0002-2460_dcabc03d-6a72-467a-8043-9eb12ce9c856",
      "PRODUCTNDC": "0002-2460",
      "PRODUCTTYPENAME": "HUMAN PRESCRIPTION DRUG",
      "PROPRIETARYNAME": "ZEPBOUND",
      "PROPRIETARYNAMESUFFIX": "",
      "NONPROPRIETARYNAME": "tirzepatide",
      "DOSAGEFORMNAME": "INJECTION, SOLUTION",
      "ROUTENAME": "SUBCUTANEOUS",
      "STARTMARKETINGDATE": 20231108,
      "ENDMARKETINGDATE": "",
      "MARKETINGCATEGORYNAME": "NDA",
      "APPLICATIONNUMBER": "NDA217806",
      "LABELERNAME": "Eli Lilly and Company",
      "SUBSTANCENAME": "TIRZEPATIDE",
      "ACTIVE_NUMERATOR_STRENGTH": 12.5,
      "ACTIVE_INGRED_UNIT": "mg/.5mL",
      "PHARM_CLASSES": "G-Protein-linked Receptor Interactions [MoA], GLP-1 Receptor Agonist [EPC], Glucagon-like Peptide-1 (GLP-1) Agonists [MoA], Glucose-dependent Insulinotropic Polypeptide Receptor Agonist [EPC]",
      "DEASCHEDULE": "",
      "NDC_EXCLUDE_FLAG": "N",
      "LISTING_RECORD_CERTIFIED_THROUGH": 20241231
    },
    {
      "PRODUCTID": "0002-2471_dcabc03d-6a72-467a-8043-9eb12ce9c856",
      "PRODUCTNDC": "0002-2471",
      "PRODUCTTYPENAME": "HUMAN PRESCRIPTION DRUG",
      "PROPRIETARYNAME": "ZEPBOUND",
      "PROPRIETARYNAMESUFFIX": "",
      "NONPROPRIETARYNAME": "tirzepatide",
      "DOSAGEFORMNAME": "INJECTION, SOLUTION",
      "ROUTENAME": "SUBCUTANEOUS",
      "STARTMARKETINGDATE": 20231108,
      "ENDMARKETINGDATE": "",
      "MARKETINGCATEGORYNAME": "NDA",
      "APPLICATIONNUMBER": "NDA217806",
      "LABELERNAME": "Eli Lilly and Company",
      "SUBSTANCENAME": "TIRZEPATIDE",
      "ACTIVE_NUMERATOR_STRENGTH": 10,
      "ACTIVE_INGRED_UNIT": "mg/.5mL",
      "PHARM_CLASSES": "G-Protein-linked Receptor Interactions [MoA], GLP-1 Receptor Agonist [EPC], Glucagon-like Peptide-1 (GLP-1) Agonists [MoA], Glucose-dependent Insulinotropic Polypeptide Receptor Agonist [EPC]",
      "DEASCHEDULE": "",
      "NDC_EXCLUDE_FLAG": "N",
      "LISTING_RECORD_CERTIFIED_THROUGH": 20241231
    },
    {
      "PRODUCTID": "0002-2484_dcabc03d-6a72-467a-8043-9eb12ce9c856",
      "PRODUCTNDC": "0002-2484",
      "PRODUCTTYPENAME": "HUMAN PRESCRIPTION DRUG",
      "PROPRIETARYNAME": "ZEPBOUND",
      "PROPRIETARYNAMESUFFIX": "",
      "NONPROPRIETARYNAME": "tirzepatide",
      "DOSAGEFORMNAME": "INJECTION, SOLUTION",
      "ROUTENAME": "SUBCUTANEOUS",
      "STARTMARKETINGDATE": 20231108,
      "ENDMARKETINGDATE": "",
      "MARKETINGCATEGORYNAME": "NDA",
      "APPLICATIONNUMBER": "NDA217806",
      "LABELERNAME": "Eli Lilly and Company",
      "SUBSTANCENAME": "TIRZEPATIDE",
      "ACTIVE_NUMERATOR_STRENGTH": 7.5,
      "ACTIVE_INGRED_UNIT": "mg/.5mL",
      "PHARM_CLASSES": "G-Protein-linked Receptor Interactions [MoA], GLP-1 Receptor Agonist [EPC], Glucagon-like Peptide-1 (GLP-1) Agonists [MoA], Glucose-dependent Insulinotropic Polypeptide Receptor Agonist [EPC]",
      "DEASCHEDULE": "",
      "NDC_EXCLUDE_FLAG": "N",
      "LISTING_RECORD_CERTIFIED_THROUGH": 20241231
    },
    {
      "PRODUCTID": "0002-2495_dcabc03d-6a72-467a-8043-9eb12ce9c856",
      "PRODUCTNDC": "0002-2495",
      "PRODUCTTYPENAME": "HUMAN PRESCRIPTION DRUG",
      "PROPRIETARYNAME": "ZEPBOUND",
      "PROPRIETARYNAMESUFFIX": "",
      "NONPROPRIETARYNAME": "tirzepatide",
      "DOSAGEFORMNAME": "INJECTION, SOLUTION",
      "ROUTENAME": "SUBCUTANEOUS",
      "STARTMARKETINGDATE": 20231108,
      "ENDMARKETINGDATE": "",
      "MARKETINGCATEGORYNAME": "NDA",
      "APPLICATIONNUMBER": "NDA217806",
      "LABELERNAME": "Eli Lilly and Company",
      "SUBSTANCENAME": "TIRZEPATIDE",
      "ACTIVE_NUMERATOR_STRENGTH": 5,
      "ACTIVE_INGRED_UNIT": "mg/.5mL",
      "PHARM_CLASSES": "G-Protein-linked Receptor Interactions [MoA], GLP-1 Receptor Agonist [EPC], Glucagon-like Peptide-1 (GLP-1) Agonists [MoA], Glucose-dependent Insulinotropic Polypeptide Receptor Agonist [EPC]",
      "DEASCHEDULE": "",
      "NDC_EXCLUDE_FLAG": "N",
      "LISTING_RECORD_CERTIFIED_THROUGH": 20241231
    },
    {
      "PRODUCTID": "0002-2506_dcabc03d-6a72-467a-8043-9eb12ce9c856",
      "PRODUCTNDC": "0002-2506",
      "PRODUCTTYPENAME": "HUMAN PRESCRIPTION DRUG",
      "PROPRIETARYNAME": "ZEPBOUND",
      "PROPRIETARYNAMESUFFIX": "",
      "NONPROPRIETARYNAME": "tirzepatide",
      "DOSAGEFORMNAME": "INJECTION, SOLUTION",
      "ROUTENAME": "SUBCUTANEOUS",
      "STARTMARKETINGDATE": 20231108,
      "ENDMARKETINGDATE": "",
      "MARKETINGCATEGORYNAME": "NDA",
      "APPLICATIONNUMBER": "NDA217806",
      "LABELERNAME": "Eli Lilly and Company",
      "SUBSTANCENAME": "TIRZEPATIDE",
      "ACTIVE_NUMERATOR_STRENGTH": 2.5,
      "ACTIVE_INGRED_UNIT": "mg/.5mL",
      "PHARM_CLASSES": "G-Protein-linked Receptor Interactions [MoA], GLP-1 Receptor Agonist [EPC], Glucagon-like Peptide-1 (GLP-1) Agonists [MoA], Glucose-dependent Insulinotropic Polypeptide Receptor Agonist [EPC]",
      "DEASCHEDULE": "",
      "NDC_EXCLUDE_FLAG": "N",
      "LISTING_RECORD_CERTIFIED_THROUGH": 20241231
    },
    {
      "PRODUCTID": "0002-2980_1ebfa429-955a-4e8b-a1bf-b77f5e790780",
      "PRODUCTNDC": "0002-2980",
      "PRODUCTTYPENAME": "HUMAN PRESCRIPTION DRUG",
      "PROPRIETARYNAME": "RETEVMO",
      "PROPRIETARYNAMESUFFIX": "",
      "NONPROPRIETARYNAME": "selpercatinib",
      "DOSAGEFORMNAME": "CAPSULE",
      "ROUTENAME": "ORAL",
      "STARTMARKETINGDATE": 20200508,
      "ENDMARKETINGDATE": "",
      "MARKETINGCATEGORYNAME": "NDA",
      "APPLICATIONNUMBER": "NDA213246",
      "LABELERNAME": "Eli Lilly and Company",
      "SUBSTANCENAME": "SELPERCATINIB",
      "ACTIVE_NUMERATOR_STRENGTH": 80,
      "ACTIVE_INGRED_UNIT": "mg/1",
      "PHARM_CLASSES": "Breast Cancer Resistance Protein Inhibitors [MoA], Cytochrome P450 2C8 Inhibitors [MoA], Cytochrome P450 3A Inhibitors [MoA], Kinase Inhibitor [EPC], Multidrug and Toxin Extrusion Transporter 1 Inhibitors [MoA], P-Glycoprotein Inhibitors [MoA], Rearranged during Transfection (RET) Inhibitors [MoA]",
      "DEASCHEDULE": "",
      "NDC_EXCLUDE_FLAG": "N",
      "LISTING_RECORD_CERTIFIED_THROUGH": 20231231
    },
    {
      "PRODUCTID": "0002-3002_b597917f-9673-4331-809d-79a538bb943c",
      "PRODUCTNDC": "0002-3002",
      "PRODUCTTYPENAME": "HUMAN PRESCRIPTION DRUG",
      "PROPRIETARYNAME": "MOUNJARO",
      "PROPRIETARYNAMESUFFIX": "",
      "NONPROPRIETARYNAME": "tirzepatide",
      "DOSAGEFORMNAME": "INJECTION, SOLUTION",
      "ROUTENAME": "SUBCUTANEOUS",
      "STARTMARKETINGDATE": 20230728,
      "ENDMARKETINGDATE": "",
      "MARKETINGCATEGORYNAME": "NDA",
      "APPLICATIONNUMBER": "NDA215866",
      "LABELERNAME": "Eli Lilly and Company",
      "SUBSTANCENAME": "TIRZEPATIDE",
      "ACTIVE_NUMERATOR_STRENGTH": 15,
      "ACTIVE_INGRED_UNIT": "mg/.5mL",
      "PHARM_CLASSES": "G-Protein-linked Receptor Interactions [MoA], GLP-1 Receptor Agonist [EPC], Glucagon-like Peptide-1 (GLP-1) Agonists [MoA], Glucose-dependent Insulinotropic Polypeptide Receptor Agonist [EPC]",
      "DEASCHEDULE": "",
      "NDC_EXCLUDE_FLAG": "N",
      "LISTING_RECORD_CERTIFIED_THROUGH": 20241231
    },
    {
      "PRODUCTID": "0002-3115_bec46346-20b5-4dbe-bac3-b8564e906941",
      "PRODUCTNDC": "0002-3115",
      "PRODUCTTYPENAME": "HUMAN PRESCRIPTION DRUG",
      "PROPRIETARYNAME": "EMGALITY",
      "PROPRIETARYNAMESUFFIX": "",
      "NONPROPRIETARYNAME": "galcanezumab-gnlm",
      "DOSAGEFORMNAME": "INJECTION, SOLUTION",
      "ROUTENAME": "SUBCUTANEOUS",
      "STARTMARKETINGDATE": 20190604,
      "ENDMARKETINGDATE": "",
      "MARKETINGCATEGORYNAME": "BLA",
      "APPLICATIONNUMBER": "BLA761063",
      "LABELERNAME": "Eli Lilly and Company",
      "SUBSTANCENAME": "GALCANEZUMAB",
      "ACTIVE_NUMERATOR_STRENGTH": 100,
      "ACTIVE_INGRED_UNIT": "mg/mL",
      "PHARM_CLASSES": "",
      "DEASCHEDULE": "",
      "NDC_EXCLUDE_FLAG": "N",
      "LISTING_RECORD_CERTIFIED_THROUGH": 20231231
    },
    {
      "PRODUCTID": "0002-3182_d89b25b3-0f8d-4cbd-b58b-44d112cd7fe6",
      "PRODUCTNDC": "0002-3182",
      "PRODUCTTYPENAME": "HUMAN PRESCRIPTION DRUG",
      "PROPRIETARYNAME": "Trulicity",
      "PROPRIETARYNAMESUFFIX": "",
      "NONPROPRIETARYNAME": "Dulaglutide",
      "DOSAGEFORMNAME": "INJECTION, SOLUTION",
      "ROUTENAME": "SUBCUTANEOUS",
      "STARTMARKETINGDATE": 20200903,
      "ENDMARKETINGDATE": "",
      "MARKETINGCATEGORYNAME": "BLA",
      "APPLICATIONNUMBER": "BLA125469",
      "LABELERNAME": "Eli Lilly and Company",
      "SUBSTANCENAME": "DULAGLUTIDE",
      "ACTIVE_NUMERATOR_STRENGTH": 4.5,
      "ACTIVE_INGRED_UNIT": "mg/.5mL",
      "PHARM_CLASSES": "GLP-1 Receptor Agonist [EPC], Glucagon-Like Peptide 1 [CS], Glucagon-like Peptide-1 (GLP-1) Agonists [MoA]",
      "DEASCHEDULE": "",
      "NDC_EXCLUDE_FLAG": "N",
      "LISTING_RECORD_CERTIFIED_THROUGH": 20241231
    },
    {
      "PRODUCTID": "0002-3227_6963b20c-fce1-414e-90b6-5d0730f93191",
      "PRODUCTNDC": "0002-3227",
      "PRODUCTTYPENAME": "HUMAN PRESCRIPTION DRUG",
      "PROPRIETARYNAME": "Strattera",
      "PROPRIETARYNAMESUFFIX": "",
      "NONPROPRIETARYNAME": "Atomoxetine hydrochloride",
      "DOSAGEFORMNAME": "CAPSULE",
      "ROUTENAME": "ORAL",
      "STARTMARKETINGDATE": 20021126,
      "ENDMARKETINGDATE": "",
      "MARKETINGCATEGORYNAME": "NDA",
      "APPLICATIONNUMBER": "NDA021411",
      "LABELERNAME": "Eli Lilly and Company",
      "SUBSTANCENAME": "ATOMOXETINE HYDROCHLORIDE",
      "ACTIVE_NUMERATOR_STRENGTH": 10,
      "ACTIVE_INGRED_UNIT": "mg/1",
      "PHARM_CLASSES": "Norepinephrine Reuptake Inhibitor [EPC], Norepinephrine Uptake Inhibitors [MoA]",
      "DEASCHEDULE": "",
      "NDC_EXCLUDE_FLAG": "N",
      "LISTING_RECORD_CERTIFIED_THROUGH": 20231231
    },
    {
      "PRODUCTID": "0002-3228_6963b20c-fce1-414e-90b6-5d0730f93191",
      "PRODUCTNDC": "0002-3228",
      "PRODUCTTYPENAME": "HUMAN PRESCRIPTION DRUG",
      "PROPRIETARYNAME": "Strattera",
      "PROPRIETARYNAMESUFFIX": "",
      "NONPROPRIETARYNAME": "Atomoxetine hydrochloride",
      "DOSAGEFORMNAME": "CAPSULE",
      "ROUTENAME": "ORAL",
      "STARTMARKETINGDATE": 20021126,
      "ENDMARKETINGDATE": "",
      "MARKETINGCATEGORYNAME": "NDA",
      "APPLICATIONNUMBER": "NDA021411",
      "LABELERNAME": "Eli Lilly and Company",
      "SUBSTANCENAME": "ATOMOXETINE HYDROCHLORIDE",
      "ACTIVE_NUMERATOR_STRENGTH": 25,
      "ACTIVE_INGRED_UNIT": "mg/1",
      "PHARM_CLASSES": "Norepinephrine Reuptake Inhibitor [EPC], Norepinephrine Uptake Inhibitors [MoA]",
      "DEASCHEDULE": "",
      "NDC_EXCLUDE_FLAG": "N",
      "LISTING_RECORD_CERTIFIED_THROUGH": 20231231
    },
    {
      "PRODUCTID": "0002-3229_6963b20c-fce1-414e-90b6-5d0730f93191",
      "PRODUCTNDC": "0002-3229",
      "PRODUCTTYPENAME": "HUMAN PRESCRIPTION DRUG",
      "PROPRIETARYNAME": "Strattera",
      "PROPRIETARYNAMESUFFIX": "",
      "NONPROPRIETARYNAME": "Atomoxetine hydrochloride",
      "DOSAGEFORMNAME": "CAPSULE",
      "ROUTENAME": "ORAL",
      "STARTMARKETINGDATE": 20021126,
      "ENDMARKETINGDATE": "",
      "MARKETINGCATEGORYNAME": "NDA",
      "APPLICATIONNUMBER": "NDA021411",
      "LABELERNAME": "Eli Lilly and Company",
      "SUBSTANCENAME": "ATOMOXETINE HYDROCHLORIDE",
      "ACTIVE_NUMERATOR_STRENGTH": 40,
      "ACTIVE_INGRED_UNIT": "mg/1",
      "PHARM_CLASSES": "Norepinephrine Reuptake Inhibitor [EPC], Norepinephrine Uptake Inhibitors [MoA]",
      "DEASCHEDULE": "",
      "NDC_EXCLUDE_FLAG": "N",
      "LISTING_RECORD_CERTIFIED_THROUGH": 20231231
    },
    {
      "PRODUCTID": "0002-3230_c0e0ab8a-6a1e-4361-b8c6-00163eaa0f7b",
      "PRODUCTNDC": "0002-3230",
      "PRODUCTTYPENAME": "HUMAN PRESCRIPTION DRUG",
      "PROPRIETARYNAME": "Symbyax",
      "PROPRIETARYNAMESUFFIX": "",
      "NONPROPRIETARYNAME": "Olanzapine and Fluoxetine hydrochloride",
      "DOSAGEFORMNAME": "CAPSULE",
      "ROUTENAME": "ORAL",
      "STARTMARKETINGDATE": 20070409,
      "ENDMARKETINGDATE": "",
      "MARKETINGCATEGORYNAME": "NDA",
      "APPLICATIONNUMBER": "NDA021520",
      "LABELERNAME": "Eli Lilly and Company",
      "SUBSTANCENAME": "FLUOXETINE HYDROCHLORIDE; OLANZAPINE",
      "ACTIVE_NUMERATOR_STRENGTH": "25; 3",
      "ACTIVE_INGRED_UNIT": "mg/1; mg/1",
      "PHARM_CLASSES": "Atypical Antipsychotic [EPC], Serotonin Reuptake Inhibitor [EPC], Serotonin Uptake Inhibitors [MoA]",
      "DEASCHEDULE": "",
      "NDC_EXCLUDE_FLAG": "N",
      "LISTING_RECORD_CERTIFIED_THROUGH": 20241231
    },
    {
      "PRODUCTID": "0002-3231_c0e0ab8a-6a1e-4361-b8c6-00163eaa0f7b",
      "PRODUCTNDC": "0002-3231",
      "PRODUCTTYPENAME": "HUMAN PRESCRIPTION DRUG",
      "PROPRIETARYNAME": "Symbyax",
      "PROPRIETARYNAMESUFFIX": "",
      "NONPROPRIETARYNAME": "Olanzapine and Fluoxetine hydrochloride",
      "DOSAGEFORMNAME": "CAPSULE",
      "ROUTENAME": "ORAL",
      "STARTMARKETINGDATE": 20031224,
      "ENDMARKETINGDATE": "",
      "MARKETINGCATEGORYNAME": "NDA",
      "APPLICATIONNUMBER": "NDA021520",
      "LABELERNAME": "Eli Lilly and Company",
      "SUBSTANCENAME": "FLUOXETINE HYDROCHLORIDE; OLANZAPINE",
      "ACTIVE_NUMERATOR_STRENGTH": "25; 6",
      "ACTIVE_INGRED_UNIT": "mg/1; mg/1",
      "PHARM_CLASSES": "Atypical Antipsychotic [EPC], Serotonin Reuptake Inhibitor [EPC], Serotonin Uptake Inhibitors [MoA]",
      "DEASCHEDULE": "",
      "NDC_EXCLUDE_FLAG": "N",
      "LISTING_RECORD_CERTIFIED_THROUGH": 20241231
    },
    {
      "PRODUCTID": "0002-3235_9b59611f-2b1b-46d7-8d7e-9d0779811309",
      "PRODUCTNDC": "0002-3235",
      "PRODUCTTYPENAME": "HUMAN PRESCRIPTION DRUG",
      "PROPRIETARYNAME": "Cymbalta",
      "PROPRIETARYNAMESUFFIX": "",
      "NONPROPRIETARYNAME": "Duloxetine hydrochloride",
      "DOSAGEFORMNAME": "CAPSULE, DELAYED RELEASE",
      "ROUTENAME": "ORAL",
      "STARTMARKETINGDATE": 20040824,
      "ENDMARKETINGDATE": "",
      "MARKETINGCATEGORYNAME": "NDA",
      "APPLICATIONNUMBER": "NDA021427",
      "LABELERNAME": "Eli Lilly and Company",
      "SUBSTANCENAME": "DULOXETINE HYDROCHLORIDE",
      "ACTIVE_NUMERATOR_STRENGTH": 20,
      "ACTIVE_INGRED_UNIT": "mg/1",
      "PHARM_CLASSES": "Norepinephrine Uptake Inhibitors [MoA], Serotonin Uptake Inhibitors [MoA], Serotonin and Norepinephrine Reuptake Inhibitor [EPC]",
      "DEASCHEDULE": "",
      "NDC_EXCLUDE_FLAG": "N",
      "LISTING_RECORD_CERTIFIED_THROUGH": 20241231
    },
    {
      "PRODUCTID": "0002-3238_6963b20c-fce1-414e-90b6-5d0730f93191",
      "PRODUCTNDC": "0002-3238",
      "PRODUCTTYPENAME": "HUMAN PRESCRIPTION DRUG",
      "PROPRIETARYNAME": "Strattera",
      "PROPRIETARYNAMESUFFIX": "",
      "NONPROPRIETARYNAME": "Atomoxetine hydrochloride",
      "DOSAGEFORMNAME": "CAPSULE",
      "ROUTENAME": "ORAL",
      "STARTMARKETINGDATE": 20021126,
      "ENDMARKETINGDATE": "",
      "MARKETINGCATEGORYNAME": "NDA",
      "APPLICATIONNUMBER": "NDA021411",
      "LABELERNAME": "Eli Lilly and Company",
      "SUBSTANCENAME": "ATOMOXETINE HYDROCHLORIDE",
      "ACTIVE_NUMERATOR_STRENGTH": 18,
      "ACTIVE_INGRED_UNIT": "mg/1",
      "PHARM_CLASSES": "Norepinephrine Reuptake Inhibitor [EPC], Norepinephrine Uptake Inhibitors [MoA]",
      "DEASCHEDULE": "",
      "NDC_EXCLUDE_FLAG": "N",
      "LISTING_RECORD_CERTIFIED_THROUGH": 20231231
    },
    {
      "PRODUCTID": "0002-3239_6963b20c-fce1-414e-90b6-5d0730f93191",
      "PRODUCTNDC": "0002-3239",
      "PRODUCTTYPENAME": "HUMAN PRESCRIPTION DRUG",
      "PROPRIETARYNAME": "Strattera",
      "PROPRIETARYNAMESUFFIX": "",
      "NONPROPRIETARYNAME": "Atomoxetine hydrochloride",
      "DOSAGEFORMNAME": "CAPSULE",
      "ROUTENAME": "ORAL",
      "STARTMARKETINGDATE": 20021126,
      "ENDMARKETINGDATE": "",
      "MARKETINGCATEGORYNAME": "NDA",
      "APPLICATIONNUMBER": "NDA021411",
      "LABELERNAME": "Eli Lilly and Company",
      "SUBSTANCENAME": "ATOMOXETINE HYDROCHLORIDE",
      "ACTIVE_NUMERATOR_STRENGTH": 60,
      "ACTIVE_INGRED_UNIT": "mg/1",
      "PHARM_CLASSES": "Norepinephrine Reuptake Inhibitor [EPC], Norepinephrine Uptake Inhibitors [MoA]",
      "DEASCHEDULE": "",
      "NDC_EXCLUDE_FLAG": "N",
      "LISTING_RECORD_CERTIFIED_THROUGH": 20231231
    },
    {
      "PRODUCTID": "0002-3240_9b59611f-2b1b-46d7-8d7e-9d0779811309",
      "PRODUCTNDC": "0002-3240",
      "PRODUCTTYPENAME": "HUMAN PRESCRIPTION DRUG",
      "PROPRIETARYNAME": "Cymbalta",
      "PROPRIETARYNAMESUFFIX": "",
      "NONPROPRIETARYNAME": "Duloxetine hydrochloride",
      "DOSAGEFORMNAME": "CAPSULE, DELAYED RELEASE",
      "ROUTENAME": "ORAL",
      "STARTMARKETINGDATE": 20040824,
      "ENDMARKETINGDATE": "",
      "MARKETINGCATEGORYNAME": "NDA",
      "APPLICATIONNUMBER": "NDA021427",
      "LABELERNAME": "Eli Lilly and Company",
      "SUBSTANCENAME": "DULOXETINE HYDROCHLORIDE",
      "ACTIVE_NUMERATOR_STRENGTH": 30,
      "ACTIVE_INGRED_UNIT": "mg/1",
      "PHARM_CLASSES": "Norepinephrine Uptake Inhibitors [MoA], Serotonin Uptake Inhibitors [MoA], Serotonin and Norepinephrine Reuptake Inhibitor [EPC]",
      "DEASCHEDULE": "",
      "NDC_EXCLUDE_FLAG": "N",
      "LISTING_RECORD_CERTIFIED_THROUGH": 20241231
    },
    {
      "PRODUCTID": "0002-3250_6963b20c-fce1-414e-90b6-5d0730f93191",
      "PRODUCTNDC": "0002-3250",
      "PRODUCTTYPENAME": "HUMAN PRESCRIPTION DRUG",
      "PROPRIETARYNAME": "Strattera",
      "PROPRIETARYNAMESUFFIX": "",
      "NONPROPRIETARYNAME": "Atomoxetine hydrochloride",
      "DOSAGEFORMNAME": "CAPSULE",
      "ROUTENAME": "ORAL",
      "STARTMARKETINGDATE": 20050214,
      "ENDMARKETINGDATE": "",
      "MARKETINGCATEGORYNAME": "NDA",
      "APPLICATIONNUMBER": "NDA021411",
      "LABELERNAME": "Eli Lilly and Company",
      "SUBSTANCENAME": "ATOMOXETINE HYDROCHLORIDE",
      "ACTIVE_NUMERATOR_STRENGTH": 80,
      "ACTIVE_INGRED_UNIT": "mg/1",
      "PHARM_CLASSES": "Norepinephrine Reuptake Inhibitor [EPC], Norepinephrine Uptake Inhibitors [MoA]",
      "DEASCHEDULE": "",
      "NDC_EXCLUDE_FLAG": "N",
      "LISTING_RECORD_CERTIFIED_THROUGH": 20231231
    },
    {
      "PRODUCTID": "0002-3251_6963b20c-fce1-414e-90b6-5d0730f93191",
      "PRODUCTNDC": "0002-3251",
      "PRODUCTTYPENAME": "HUMAN PRESCRIPTION DRUG",
      "PROPRIETARYNAME": "Strattera",
      "PROPRIETARYNAMESUFFIX": "",
      "NONPROPRIETARYNAME": "Atomoxetine hydrochloride",
      "DOSAGEFORMNAME": "CAPSULE",
      "ROUTENAME": "ORAL",
      "STARTMARKETINGDATE": 20050214,
      "ENDMARKETINGDATE": "",
      "MARKETINGCATEGORYNAME": "NDA",
      "APPLICATIONNUMBER": "NDA021411",
      "LABELERNAME": "Eli Lilly and Company",
      "SUBSTANCENAME": "ATOMOXETINE HYDROCHLORIDE",
      "ACTIVE_NUMERATOR_STRENGTH": 100,
      "ACTIVE_INGRED_UNIT": "mg/1",
      "PHARM_CLASSES": "Norepinephrine Reuptake Inhibitor [EPC], Norepinephrine Uptake Inhibitors [MoA]",
      "DEASCHEDULE": "",
      "NDC_EXCLUDE_FLAG": "N",
      "LISTING_RECORD_CERTIFIED_THROUGH": 20231231
    },
    {
      "PRODUCTID": "0002-3270_9b59611f-2b1b-46d7-8d7e-9d0779811309",
      "PRODUCTNDC": "0002-3270",
      "PRODUCTTYPENAME": "HUMAN PRESCRIPTION DRUG",
      "PROPRIETARYNAME": "Cymbalta",
      "PROPRIETARYNAMESUFFIX": "",
      "NONPROPRIETARYNAME": "Duloxetine hydrochloride",
      "DOSAGEFORMNAME": "CAPSULE, DELAYED RELEASE",
      "ROUTENAME": "ORAL",
      "STARTMARKETINGDATE": 20100115,
      "ENDMARKETINGDATE": "",
      "MARKETINGCATEGORYNAME": "NDA",
      "APPLICATIONNUMBER": "NDA021427",
      "LABELERNAME": "Eli Lilly and Company",
      "SUBSTANCENAME": "DULOXETINE HYDROCHLORIDE",
      "ACTIVE_NUMERATOR_STRENGTH": 60,
      "ACTIVE_INGRED_UNIT": "mg/1",
      "PHARM_CLASSES": "Norepinephrine Uptake Inhibitors [MoA], Serotonin Uptake Inhibitors [MoA], Serotonin and Norepinephrine Reuptake Inhibitor [EPC]",
      "DEASCHEDULE": "",
      "NDC_EXCLUDE_FLAG": "N",
      "LISTING_RECORD_CERTIFIED_THROUGH": 20241231
    },
    {
      "PRODUCTID": "0002-3977_1ebfa429-955a-4e8b-a1bf-b77f5e790780",
      "PRODUCTNDC": "0002-3977",
      "PRODUCTTYPENAME": "HUMAN PRESCRIPTION DRUG",
      "PROPRIETARYNAME": "RETEVMO",
      "PROPRIETARYNAMESUFFIX": "",
      "NONPROPRIETARYNAME": "selpercatinib",
      "DOSAGEFORMNAME": "CAPSULE",
      "ROUTENAME": "ORAL",
      "STARTMARKETINGDATE": 20200508,
      "ENDMARKETINGDATE": "",
      "MARKETINGCATEGORYNAME": "NDA",
      "APPLICATIONNUMBER": "NDA213246",
      "LABELERNAME": "Eli Lilly and Company",
      "SUBSTANCENAME": "SELPERCATINIB",
      "ACTIVE_NUMERATOR_STRENGTH": 40,
      "ACTIVE_INGRED_UNIT": "mg/1",
      "PHARM_CLASSES": "Breast Cancer Resistance Protein Inhibitors [MoA], Cytochrome P450 2C8 Inhibitors [MoA], Cytochrome P450 3A Inhibitors [MoA], Kinase Inhibitor [EPC], Multidrug and Toxin Extrusion Transporter 1 Inhibitors [MoA], P-Glycoprotein Inhibitors [MoA], Rearranged during Transfection (RET) Inhibitors [MoA]",
      "DEASCHEDULE": "",
      "NDC_EXCLUDE_FLAG": "N",
      "LISTING_RECORD_CERTIFIED_THROUGH": 20231231
    },
    {
      "PRODUCTID": "0002-4112_8008d181-4679-4320-a624-0072056c40c7",
      "PRODUCTNDC": "0002-4112",
      "PRODUCTTYPENAME": "HUMAN PRESCRIPTION DRUG",
      "PROPRIETARYNAME": "Zyprexa",
      "PROPRIETARYNAMESUFFIX": "",
      "NONPROPRIETARYNAME": "Olanzapine",
      "DOSAGEFORMNAME": "TABLET",
      "ROUTENAME": "ORAL",
      "STARTMARKETINGDATE": 19970623,
      "ENDMARKETINGDATE": "",
      "MARKETINGCATEGORYNAME": "NDA",
      "APPLICATIONNUMBER": "NDA020592",
      "LABELERNAME": "Eli Lilly and Company",
      "SUBSTANCENAME": "OLANZAPINE",
      "ACTIVE_NUMERATOR_STRENGTH": 2.5,
      "ACTIVE_INGRED_UNIT": "mg/1",
      "PHARM_CLASSES": "Atypical Antipsychotic [EPC]",
      "DEASCHEDULE": "",
      "NDC_EXCLUDE_FLAG": "N",
      "LISTING_RECORD_CERTIFIED_THROUGH": 20231231
    },
    {
      "PRODUCTID": "0002-4115_8008d181-4679-4320-a624-0072056c40c7",
      "PRODUCTNDC": "0002-4115",
      "PRODUCTTYPENAME": "HUMAN PRESCRIPTION DRUG",
      "PROPRIETARYNAME": "Zyprexa",
      "PROPRIETARYNAMESUFFIX": "",
      "NONPROPRIETARYNAME": "Olanzapine",
      "DOSAGEFORMNAME": "TABLET",
      "ROUTENAME": "ORAL",
      "STARTMARKETINGDATE": 19961001,
      "ENDMARKETINGDATE": "",
      "MARKETINGCATEGORYNAME": "NDA",
      "APPLICATIONNUMBER": "NDA020592",
      "LABELERNAME": "Eli Lilly and Company",
      "SUBSTANCENAME": "OLANZAPINE",
      "ACTIVE_NUMERATOR_STRENGTH": 5,
      "ACTIVE_INGRED_UNIT": "mg/1",
      "PHARM_CLASSES": "Atypical Antipsychotic [EPC]",
      "DEASCHEDULE": "",
      "NDC_EXCLUDE_FLAG": "N",
      "LISTING_RECORD_CERTIFIED_THROUGH": 20231231
    },
    {
      "PRODUCTID": "0002-4116_8008d181-4679-4320-a624-0072056c40c7",
      "PRODUCTNDC": "0002-4116",
      "PRODUCTTYPENAME": "HUMAN PRESCRIPTION DRUG",
      "PROPRIETARYNAME": "Zyprexa",
      "PROPRIETARYNAMESUFFIX": "",
      "NONPROPRIETARYNAME": "Olanzapine",
      "DOSAGEFORMNAME": "TABLET",
      "ROUTENAME": "ORAL",
      "STARTMARKETINGDATE": 19961001,
      "ENDMARKETINGDATE": "",
      "MARKETINGCATEGORYNAME": "NDA",
      "APPLICATIONNUMBER": "NDA020592",
      "LABELERNAME": "Eli Lilly and Company",
      "SUBSTANCENAME": "OLANZAPINE",
      "ACTIVE_NUMERATOR_STRENGTH": 7.5,
      "ACTIVE_INGRED_UNIT": "mg/1",
      "PHARM_CLASSES": "Atypical Antipsychotic [EPC]",
      "DEASCHEDULE": "",
      "NDC_EXCLUDE_FLAG": "N",
      "LISTING_RECORD_CERTIFIED_THROUGH": 20231231
    },
    {
      "PRODUCTID": "0002-4117_8008d181-4679-4320-a624-0072056c40c7",
      "PRODUCTNDC": "0002-4117",
      "PRODUCTTYPENAME": "HUMAN PRESCRIPTION DRUG",
      "PROPRIETARYNAME": "Zyprexa",
      "PROPRIETARYNAMESUFFIX": "",
      "NONPROPRIETARYNAME": "Olanzapine",
      "DOSAGEFORMNAME": "TABLET",
      "ROUTENAME": "ORAL",
      "STARTMARKETINGDATE": 19961001,
      "ENDMARKETINGDATE": "",
      "MARKETINGCATEGORYNAME": "NDA",
      "APPLICATIONNUMBER": "NDA020592",
      "LABELERNAME": "Eli Lilly and Company",
      "SUBSTANCENAME": "OLANZAPINE",
      "ACTIVE_NUMERATOR_STRENGTH": 10,
      "ACTIVE_INGRED_UNIT": "mg/1",
      "PHARM_CLASSES": "Atypical Antipsychotic [EPC]",
      "DEASCHEDULE": "",
      "NDC_EXCLUDE_FLAG": "N",
      "LISTING_RECORD_CERTIFIED_THROUGH": 20231231
    },
    {
      "PRODUCTID": "0002-4182_44ded0f7-8c82-4875-ad44-db5b0354a094",
      "PRODUCTNDC": "0002-4182",
      "PRODUCTTYPENAME": "HUMAN PRESCRIPTION DRUG",
      "PROPRIETARYNAME": "Olumiant",
      "PROPRIETARYNAMESUFFIX": "",
      "NONPROPRIETARYNAME": "baricitinib",
      "DOSAGEFORMNAME": "TABLET, FILM COATED",
      "ROUTENAME": "ORAL",
      "STARTMARKETINGDATE": 20180531,
      "ENDMARKETINGDATE": "",
      "MARKETINGCATEGORYNAME": "NDA",
      "APPLICATIONNUMBER": "NDA207924",
      "LABELERNAME": "Eli Lilly and Company",
      "SUBSTANCENAME": "BARICITINIB",
      "ACTIVE_NUMERATOR_STRENGTH": 2,
      "ACTIVE_INGRED_UNIT": "mg/1",
      "PHARM_CLASSES": "Janus Kinase Inhibitor [EPC], Janus Kinase Inhibitors [MoA]",
      "DEASCHEDULE": "",
      "NDC_EXCLUDE_FLAG": "N",
      "LISTING_RECORD_CERTIFIED_THROUGH": 20241231
    },
    {
      "PRODUCTID": "0002-4184_736ef754-5dd5-422b-81fa-bf12e9ee8afb",
      "PRODUCTNDC": "0002-4184",
      "PRODUCTTYPENAME": "HUMAN PRESCRIPTION DRUG",
      "PROPRIETARYNAME": "Evista",
      "PROPRIETARYNAMESUFFIX": "",
      "NONPROPRIETARYNAME": "Raloxifene hydrochloride",
      "DOSAGEFORMNAME": "TABLET",
      "ROUTENAME": "ORAL",
      "STARTMARKETINGDATE": 19980106,
      "ENDMARKETINGDATE": "",
      "MARKETINGCATEGORYNAME": "NDA",
      "APPLICATIONNUMBER": "NDA020815",
      "LABELERNAME": "Eli Lilly and Company",
      "SUBSTANCENAME": "RALOXIFENE HYDROCHLORIDE",
      "ACTIVE_NUMERATOR_STRENGTH": 60,
      "ACTIVE_INGRED_UNIT": "mg/1",
      "PHARM_CLASSES": "Estrogen Agonist/Antagonist [EPC], Selective Estrogen Receptor Modulators [MoA]",
      "DEASCHEDULE": "",
      "NDC_EXCLUDE_FLAG": "N",
      "LISTING_RECORD_CERTIFIED_THROUGH": 20241231
    },
    {
      "PRODUCTID": "0002-4312_5ef14cf2-d634-4a7b-9254-4cc480e8a48d",
      "PRODUCTNDC": "0002-4312",
      "PRODUCTTYPENAME": "HUMAN PRESCRIPTION DRUG",
      "PROPRIETARYNAME": "Reyvow",
      "PROPRIETARYNAMESUFFIX": "",
      "NONPROPRIETARYNAME": "lasmiditan",
      "DOSAGEFORMNAME": "TABLET",
      "ROUTENAME": "ORAL",
      "STARTMARKETINGDATE": 20191011,
      "ENDMARKETINGDATE": "",
      "MARKETINGCATEGORYNAME": "NDA",
      "APPLICATIONNUMBER": "NDA211280",
      "LABELERNAME": "Eli Lilly and Company",
      "SUBSTANCENAME": "LASMIDITAN",
      "ACTIVE_NUMERATOR_STRENGTH": 50,
      "ACTIVE_INGRED_UNIT": "mg/1",
      "PHARM_CLASSES": "",
      "DEASCHEDULE": "CV",
      "NDC_EXCLUDE_FLAG": "N",
      "LISTING_RECORD_CERTIFIED_THROUGH": 20231231
    },
    {
      "PRODUCTID": "0002-4415_8008d181-4679-4320-a624-0072056c40c7",
      "PRODUCTNDC": "0002-4415",
      "PRODUCTTYPENAME": "HUMAN PRESCRIPTION DRUG",
      "PROPRIETARYNAME": "Zyprexa",
      "PROPRIETARYNAMESUFFIX": "",
      "NONPROPRIETARYNAME": "Olanzapine",
      "DOSAGEFORMNAME": "TABLET",
      "ROUTENAME": "ORAL",
      "STARTMARKETINGDATE": 20000110,
      "ENDMARKETINGDATE": "",
      "MARKETINGCATEGORYNAME": "NDA",
      "APPLICATIONNUMBER": "NDA020592",
      "LABELERNAME": "Eli Lilly and Company",
      "SUBSTANCENAME": "OLANZAPINE",
      "ACTIVE_NUMERATOR_STRENGTH": 15,
      "ACTIVE_INGRED_UNIT": "mg/1",
      "PHARM_CLASSES": "Atypical Antipsychotic [EPC]",
      "DEASCHEDULE": "",
      "NDC_EXCLUDE_FLAG": "N",
      "LISTING_RECORD_CERTIFIED_THROUGH": 20231231
    },
    {
      "PRODUCTID": "0002-4420_8008d181-4679-4320-a624-0072056c40c7",
      "PRODUCTNDC": "0002-4420",
      "PRODUCTTYPENAME": "HUMAN PRESCRIPTION DRUG",
      "PROPRIETARYNAME": "Zyprexa",
      "PROPRIETARYNAMESUFFIX": "",
      "NONPROPRIETARYNAME": "Olanzapine",
      "DOSAGEFORMNAME": "TABLET",
      "ROUTENAME": "ORAL",
      "STARTMARKETINGDATE": 20010301,
      "ENDMARKETINGDATE": "",
      "MARKETINGCATEGORYNAME": "NDA",
      "APPLICATIONNUMBER": "NDA020592",
      "LABELERNAME": "Eli Lilly and Company",
      "SUBSTANCENAME": "OLANZAPINE",
      "ACTIVE_NUMERATOR_STRENGTH": 20,
      "ACTIVE_INGRED_UNIT": "mg/1",
      "PHARM_CLASSES": "Atypical Antipsychotic [EPC]",
      "DEASCHEDULE": "",
      "NDC_EXCLUDE_FLAG": "N",
      "LISTING_RECORD_CERTIFIED_THROUGH": 20231231
    },
    {
      "PRODUCTID": "0002-4453_8008d181-4679-4320-a624-0072056c40c7",
      "PRODUCTNDC": "0002-4453",
      "PRODUCTTYPENAME": "HUMAN PRESCRIPTION DRUG",
      "PROPRIETARYNAME": "ZYPREXA",
      "PROPRIETARYNAMESUFFIX": "Zydis",
      "NONPROPRIETARYNAME": "Olanzapine",
      "DOSAGEFORMNAME": "TABLET, ORALLY DISINTEGRATING",
      "ROUTENAME": "ORAL",
      "STARTMARKETINGDATE": 20000601,
      "ENDMARKETINGDATE": "",
      "MARKETINGCATEGORYNAME": "NDA",
      "APPLICATIONNUMBER": "NDA021086",
      "LABELERNAME": "Eli Lilly and Company",
      "SUBSTANCENAME": "OLANZAPINE",
      "ACTIVE_NUMERATOR_STRENGTH": 5,
      "ACTIVE_INGRED_UNIT": "mg/1",
      "PHARM_CLASSES": "Atypical Antipsychotic [EPC]",
      "DEASCHEDULE": "",
      "NDC_EXCLUDE_FLAG": "N",
      "LISTING_RECORD_CERTIFIED_THROUGH": 20231231
    },
    {
      "PRODUCTID": "0002-4454_8008d181-4679-4320-a624-0072056c40c7",
      "PRODUCTNDC": "0002-4454",
      "PRODUCTTYPENAME": "HUMAN PRESCRIPTION DRUG",
      "PROPRIETARYNAME": "ZYPREXA",
      "PROPRIETARYNAMESUFFIX": "Zydis",
      "NONPROPRIETARYNAME": "Olanzapine",
      "DOSAGEFORMNAME": "TABLET, ORALLY DISINTEGRATING",
      "ROUTENAME": "ORAL",
      "STARTMARKETINGDATE": 20000601,
      "ENDMARKETINGDATE": "",
      "MARKETINGCATEGORYNAME": "NDA",
      "APPLICATIONNUMBER": "NDA021086",
      "LABELERNAME": "Eli Lilly and Company",
      "SUBSTANCENAME": "OLANZAPINE",
      "ACTIVE_NUMERATOR_STRENGTH": 10,
      "ACTIVE_INGRED_UNIT": "mg/1",
      "PHARM_CLASSES": "Atypical Antipsychotic [EPC]",
      "DEASCHEDULE": "",
      "NDC_EXCLUDE_FLAG": "N",
      "LISTING_RECORD_CERTIFIED_THROUGH": 20231231
    },
    {
      "PRODUCTID": "0002-4455_8008d181-4679-4320-a624-0072056c40c7",
      "PRODUCTNDC": "0002-4455",
      "PRODUCTTYPENAME": "HUMAN PRESCRIPTION DRUG",
      "PROPRIETARYNAME": "ZYPREXA",
      "PROPRIETARYNAMESUFFIX": "Zydis",
      "NONPROPRIETARYNAME": "Olanzapine",
      "DOSAGEFORMNAME": "TABLET, ORALLY DISINTEGRATING",
      "ROUTENAME": "ORAL",
      "STARTMARKETINGDATE": 20010901,
      "ENDMARKETINGDATE": "",
      "MARKETINGCATEGORYNAME": "NDA",
      "APPLICATIONNUMBER": "NDA021086",
      "LABELERNAME": "Eli Lilly and Company",
      "SUBSTANCENAME": "OLANZAPINE",
      "ACTIVE_NUMERATOR_STRENGTH": 15,
      "ACTIVE_INGRED_UNIT": "mg/1",
      "PHARM_CLASSES": "Atypical Antipsychotic [EPC]",
      "DEASCHEDULE": "",
      "NDC_EXCLUDE_FLAG": "N",
      "LISTING_RECORD_CERTIFIED_THROUGH": 20231231
    },
    {
      "PRODUCTID": "0002-4456_8008d181-4679-4320-a624-0072056c40c7",
      "PRODUCTNDC": "0002-4456",
      "PRODUCTTYPENAME": "HUMAN PRESCRIPTION DRUG",
      "PROPRIETARYNAME": "ZYPREXA",
      "PROPRIETARYNAMESUFFIX": "Zydis",
      "NONPROPRIETARYNAME": "Olanzapine",
      "DOSAGEFORMNAME": "TABLET, ORALLY DISINTEGRATING",
      "ROUTENAME": "ORAL",
      "STARTMARKETINGDATE": 20010901,
      "ENDMARKETINGDATE": "",
      "MARKETINGCATEGORYNAME": "NDA",
      "APPLICATIONNUMBER": "NDA021086",
      "LABELERNAME": "Eli Lilly and Company",
      "SUBSTANCENAME": "OLANZAPINE",
      "ACTIVE_NUMERATOR_STRENGTH": 20,
      "ACTIVE_INGRED_UNIT": "mg/1",
      "PHARM_CLASSES": "Atypical Antipsychotic [EPC]",
      "DEASCHEDULE": "",
      "NDC_EXCLUDE_FLAG": "N",
      "LISTING_RECORD_CERTIFIED_THROUGH": 20231231
    },
    {
      "PRODUCTID": "0002-4462_21516130-0eb4-48d3-ba98-80465523793a",
      "PRODUCTNDC": "0002-4462",
      "PRODUCTTYPENAME": "HUMAN PRESCRIPTION DRUG",
      "PROPRIETARYNAME": "Cialis",
      "PROPRIETARYNAMESUFFIX": "",
      "NONPROPRIETARYNAME": "Tadalafil",
      "DOSAGEFORMNAME": "TABLET, FILM COATED",
      "ROUTENAME": "ORAL",
      "STARTMARKETINGDATE": 20031126,
      "ENDMARKETINGDATE": "",
      "MARKETINGCATEGORYNAME": "NDA",
      "APPLICATIONNUMBER": "NDA021368",
      "LABELERNAME": "Eli Lilly and Company",
      "SUBSTANCENAME": "TADALAFIL",
      "ACTIVE_NUMERATOR_STRENGTH": 5,
      "ACTIVE_INGRED_UNIT": "mg/1",
      "PHARM_CLASSES": "Phosphodiesterase 5 Inhibitor [EPC], Phosphodiesterase 5 Inhibitors [MoA]",
      "DEASCHEDULE": "",
      "NDC_EXCLUDE_FLAG": "N",
      "LISTING_RECORD_CERTIFIED_THROUGH": 20241231
    },
    {
      "PRODUCTID": "0002-4463_21516130-0eb4-48d3-ba98-80465523793a",
      "PRODUCTNDC": "0002-4463",
      "PRODUCTTYPENAME": "HUMAN PRESCRIPTION DRUG",
      "PROPRIETARYNAME": "Cialis",
      "PROPRIETARYNAMESUFFIX": "",
      "NONPROPRIETARYNAME": "Tadalafil",
      "DOSAGEFORMNAME": "TABLET, FILM COATED",
      "ROUTENAME": "ORAL",
      "STARTMARKETINGDATE": 20031126,
      "ENDMARKETINGDATE": "",
      "MARKETINGCATEGORYNAME": "NDA",
      "APPLICATIONNUMBER": "NDA021368",
      "LABELERNAME": "Eli Lilly and Company",
      "SUBSTANCENAME": "TADALAFIL",
      "ACTIVE_NUMERATOR_STRENGTH": 10,
      "ACTIVE_INGRED_UNIT": "mg/1",
      "PHARM_CLASSES": "Phosphodiesterase 5 Inhibitor [EPC], Phosphodiesterase 5 Inhibitors [MoA]",
      "DEASCHEDULE": "",
      "NDC_EXCLUDE_FLAG": "N",
      "LISTING_RECORD_CERTIFIED_THROUGH": 20241231
    },
    {
      "PRODUCTID": "0002-4464_21516130-0eb4-48d3-ba98-80465523793a",
      "PRODUCTNDC": "0002-4464",
      "PRODUCTTYPENAME": "HUMAN PRESCRIPTION DRUG",
      "PROPRIETARYNAME": "Cialis",
      "PROPRIETARYNAMESUFFIX": "",
      "NONPROPRIETARYNAME": "Tadalafil",
      "DOSAGEFORMNAME": "TABLET, FILM COATED",
      "ROUTENAME": "ORAL",
      "STARTMARKETINGDATE": 20031126,
      "ENDMARKETINGDATE": "",
      "MARKETINGCATEGORYNAME": "NDA",
      "APPLICATIONNUMBER": "NDA021368",
      "LABELERNAME": "Eli Lilly and Company",
      "SUBSTANCENAME": "TADALAFIL",
      "ACTIVE_NUMERATOR_STRENGTH": 20,
      "ACTIVE_INGRED_UNIT": "mg/1",
      "PHARM_CLASSES": "Phosphodiesterase 5 Inhibitor [EPC], Phosphodiesterase 5 Inhibitors [MoA]",
      "DEASCHEDULE": "",
      "NDC_EXCLUDE_FLAG": "N",
      "LISTING_RECORD_CERTIFIED_THROUGH": 20241231
    },
    {
      "PRODUCTID": "0002-4465_21516130-0eb4-48d3-ba98-80465523793a",
      "PRODUCTNDC": "0002-4465",
      "PRODUCTTYPENAME": "HUMAN PRESCRIPTION DRUG",
      "PROPRIETARYNAME": "Cialis",
      "PROPRIETARYNAMESUFFIX": "",
      "NONPROPRIETARYNAME": "Tadalafil",
      "DOSAGEFORMNAME": "TABLET, FILM COATED",
      "ROUTENAME": "ORAL",
      "STARTMARKETINGDATE": 20080107,
      "ENDMARKETINGDATE": "",
      "MARKETINGCATEGORYNAME": "NDA",
      "APPLICATIONNUMBER": "NDA021368",
      "LABELERNAME": "Eli Lilly and Company",
      "SUBSTANCENAME": "TADALAFIL",
      "ACTIVE_NUMERATOR_STRENGTH": 2.5,
      "ACTIVE_INGRED_UNIT": "mg/1",
      "PHARM_CLASSES": "Phosphodiesterase 5 Inhibitor [EPC], Phosphodiesterase 5 Inhibitors [MoA]",
      "DEASCHEDULE": "",
      "NDC_EXCLUDE_FLAG": "N",
      "LISTING_RECORD_CERTIFIED_THROUGH": 20241231
    },
    {
      "PRODUCTID": "0002-4479_44ded0f7-8c82-4875-ad44-db5b0354a094",
      "PRODUCTNDC": "0002-4479",
      "PRODUCTTYPENAME": "HUMAN PRESCRIPTION DRUG",
      "PROPRIETARYNAME": "Olumiant",
      "PROPRIETARYNAMESUFFIX": "",
      "NONPROPRIETARYNAME": "baricitinib",
      "DOSAGEFORMNAME": "TABLET, FILM COATED",
      "ROUTENAME": "ORAL",
      "STARTMARKETINGDATE": 20220510,
      "ENDMARKETINGDATE": "",
      "MARKETINGCATEGORYNAME": "NDA",
      "APPLICATIONNUMBER": "NDA207924",
      "LABELERNAME": "Eli Lilly and Company",
      "SUBSTANCENAME": "BARICITINIB",
      "ACTIVE_NUMERATOR_STRENGTH": 4,
      "ACTIVE_INGRED_UNIT": "mg/1",
      "PHARM_CLASSES": "Janus Kinase Inhibitor [EPC], Janus Kinase Inhibitors [MoA]",
      "DEASCHEDULE": "",
      "NDC_EXCLUDE_FLAG": "N",
      "LISTING_RECORD_CERTIFIED_THROUGH": 20241231
    },
    {
      "PRODUCTID": "0002-4483_7ae944a7-1113-4e55-b06d-1ecf3c2a175e",
      "PRODUCTNDC": "0002-4483",
      "PRODUCTTYPENAME": "HUMAN PRESCRIPTION DRUG",
      "PROPRIETARYNAME": "Verzenio",
      "PROPRIETARYNAMESUFFIX": "",
      "NONPROPRIETARYNAME": "abemaciclib",
      "DOSAGEFORMNAME": "TABLET",
      "ROUTENAME": "ORAL",
      "STARTMARKETINGDATE": 20170928,
      "ENDMARKETINGDATE": "",
      "MARKETINGCATEGORYNAME": "NDA",
      "APPLICATIONNUMBER": "NDA208716",
      "LABELERNAME": "Eli Lilly and Company",
      "SUBSTANCENAME": "ABEMACICLIB",
      "ACTIVE_NUMERATOR_STRENGTH": 50,
      "ACTIVE_INGRED_UNIT": "mg/1",
      "PHARM_CLASSES": "Kinase Inhibitor [EPC], Kinase Inhibitors [MoA]",
      "DEASCHEDULE": "",
      "NDC_EXCLUDE_FLAG": "N",
      "LISTING_RECORD_CERTIFIED_THROUGH": 20241231
    },
    {
      "PRODUCTID": "0002-4491_5ef14cf2-d634-4a7b-9254-4cc480e8a48d",
      "PRODUCTNDC": "0002-4491",
      "PRODUCTTYPENAME": "HUMAN PRESCRIPTION DRUG",
      "PROPRIETARYNAME": "Reyvow",
      "PROPRIETARYNAMESUFFIX": "",
      "NONPROPRIETARYNAME": "lasmiditan",
      "DOSAGEFORMNAME": "TABLET",
      "ROUTENAME": "ORAL",
      "STARTMARKETINGDATE": 20191011,
      "ENDMARKETINGDATE": "",
      "MARKETINGCATEGORYNAME": "NDA",
      "APPLICATIONNUMBER": "NDA211280",
      "LABELERNAME": "Eli Lilly and Company",
      "SUBSTANCENAME": "LASMIDITAN",
      "ACTIVE_NUMERATOR_STRENGTH": 100,
      "ACTIVE_INGRED_UNIT": "mg/1",
      "PHARM_CLASSES": "",
      "DEASCHEDULE": "CV",
      "NDC_EXCLUDE_FLAG": "N",
      "LISTING_RECORD_CERTIFIED_THROUGH": 20231231
    },
    {
      "PRODUCTID": "0002-4732_44ded0f7-8c82-4875-ad44-db5b0354a094",
      "PRODUCTNDC": "0002-4732",
      "PRODUCTTYPENAME": "HUMAN PRESCRIPTION DRUG",
      "PROPRIETARYNAME": "Olumiant",
      "PROPRIETARYNAMESUFFIX": "",
      "NONPROPRIETARYNAME": "baricitinib",
      "DOSAGEFORMNAME": "TABLET, FILM COATED",
      "ROUTENAME": "ORAL",
      "STARTMARKETINGDATE": 20191008,
      "ENDMARKETINGDATE": "",
      "MARKETINGCATEGORYNAME": "NDA",
      "APPLICATIONNUMBER": "NDA207924",
      "LABELERNAME": "Eli Lilly and Company",
      "SUBSTANCENAME": "BARICITINIB",
      "ACTIVE_NUMERATOR_STRENGTH": 1,
      "ACTIVE_INGRED_UNIT": "mg/1",
      "PHARM_CLASSES": "Janus Kinase Inhibitor [EPC], Janus Kinase Inhibitors [MoA]",
      "DEASCHEDULE": "",
      "NDC_EXCLUDE_FLAG": "N",
      "LISTING_RECORD_CERTIFIED_THROUGH": 20241231
    },
    {
      "PRODUCTID": "0002-4815_7ae944a7-1113-4e55-b06d-1ecf3c2a175e",
      "PRODUCTNDC": "0002-4815",
      "PRODUCTTYPENAME": "HUMAN PRESCRIPTION DRUG",
      "PROPRIETARYNAME": "Verzenio",
      "PROPRIETARYNAMESUFFIX": "",
      "NONPROPRIETARYNAME": "abemaciclib",
      "DOSAGEFORMNAME": "TABLET",
      "ROUTENAME": "ORAL",
      "STARTMARKETINGDATE": 20170928,
      "ENDMARKETINGDATE": "",
      "MARKETINGCATEGORYNAME": "NDA",
      "APPLICATIONNUMBER": "NDA208716",
      "LABELERNAME": "Eli Lilly and Company",
      "SUBSTANCENAME": "ABEMACICLIB",
      "ACTIVE_NUMERATOR_STRENGTH": 100,
      "ACTIVE_INGRED_UNIT": "mg/1",
      "PHARM_CLASSES": "Kinase Inhibitor [EPC], Kinase Inhibitors [MoA]",
      "DEASCHEDULE": "",
      "NDC_EXCLUDE_FLAG": "N",
      "LISTING_RECORD_CERTIFIED_THROUGH": 20241231
    },
    {
      "PRODUCTID": "0002-5337_7ae944a7-1113-4e55-b06d-1ecf3c2a175e",
      "PRODUCTNDC": "0002-5337",
      "PRODUCTTYPENAME": "HUMAN PRESCRIPTION DRUG",
      "PROPRIETARYNAME": "Verzenio",
      "PROPRIETARYNAMESUFFIX": "",
      "NONPROPRIETARYNAME": "abemaciclib",
      "DOSAGEFORMNAME": "TABLET",
      "ROUTENAME": "ORAL",
      "STARTMARKETINGDATE": 20170928,
      "ENDMARKETINGDATE": "",
      "MARKETINGCATEGORYNAME": "NDA",
      "APPLICATIONNUMBER": "NDA208716",
      "LABELERNAME": "Eli Lilly and Company",
      "SUBSTANCENAME": "ABEMACICLIB",
      "ACTIVE_NUMERATOR_STRENGTH": 150,
      "ACTIVE_INGRED_UNIT": "mg/1",
      "PHARM_CLASSES": "Kinase Inhibitor [EPC], Kinase Inhibitors [MoA]",
      "DEASCHEDULE": "",
      "NDC_EXCLUDE_FLAG": "N",
      "LISTING_RECORD_CERTIFIED_THROUGH": 20241231
    },
    {
      "PRODUCTID": "0002-6145_f88837b4-7c0d-4200-aba0-e92561310058",
      "PRODUCTNDC": "0002-6145",
      "PRODUCTTYPENAME": "HUMAN PRESCRIPTION DRUG",
      "PROPRIETARYNAME": "Baqsimi",
      "PROPRIETARYNAMESUFFIX": "",
      "NONPROPRIETARYNAME": "glucagon",
      "DOSAGEFORMNAME": "POWDER",
      "ROUTENAME": "NASAL",
      "STARTMARKETINGDATE": 20190724,
      "ENDMARKETINGDATE": "",
      "MARKETINGCATEGORYNAME": "NDA",
      "APPLICATIONNUMBER": "NDA210134",
      "LABELERNAME": "Eli Lilly and Company",
      "SUBSTANCENAME": "GLUCAGON",
      "ACTIVE_NUMERATOR_STRENGTH": 3,
      "ACTIVE_INGRED_UNIT": "mg/1",
      "PHARM_CLASSES": "Antihypoglycemic Agent [EPC], Decreased GI Motility [PE], Decreased GI Smooth Muscle Tone [PE], Decreased Glycolysis [PE], Gastrointestinal Motility Inhibitor [EPC], Increased Gluconeogenesis [PE], Increased Glycogenolysis [PE]",
      "DEASCHEDULE": "",
      "NDC_EXCLUDE_FLAG": "N",
      "LISTING_RECORD_CERTIFIED_THROUGH": 20231231
    },
    {
      "PRODUCTID": "0002-6216_7ae944a7-1113-4e55-b06d-1ecf3c2a175e",
      "PRODUCTNDC": "0002-6216",
      "PRODUCTTYPENAME": "HUMAN PRESCRIPTION DRUG",
      "PROPRIETARYNAME": "Verzenio",
      "PROPRIETARYNAMESUFFIX": "",
      "NONPROPRIETARYNAME": "abemaciclib",
      "DOSAGEFORMNAME": "TABLET",
      "ROUTENAME": "ORAL",
      "STARTMARKETINGDATE": 20170928,
      "ENDMARKETINGDATE": "",
      "MARKETINGCATEGORYNAME": "NDA",
      "APPLICATIONNUMBER": "NDA208716",
      "LABELERNAME": "Eli Lilly and Company",
      "SUBSTANCENAME": "ABEMACICLIB",
      "ACTIVE_NUMERATOR_STRENGTH": 200,
      "ACTIVE_INGRED_UNIT": "mg/1",
      "PHARM_CLASSES": "Kinase Inhibitor [EPC], Kinase Inhibitors [MoA]",
      "DEASCHEDULE": "",
      "NDC_EXCLUDE_FLAG": "N",
      "LISTING_RECORD_CERTIFIED_THROUGH": 20241231
    },
    {
      "PRODUCTID": "0002-6885_14a2ffe3-1d7e-4d1b-ac44-1698d5f92da4",
      "PRODUCTNDC": "0002-6885",
      "PRODUCTTYPENAME": "HUMAN PRESCRIPTION DRUG",
      "PROPRIETARYNAME": "Baricitinib",
      "PROPRIETARYNAMESUFFIX": "",
      "NONPROPRIETARYNAME": "baricitinib",
      "DOSAGEFORMNAME": "TABLET, FILM COATED",
      "ROUTENAME": "ORAL",
      "STARTMARKETINGDATE": 20211220,
      "ENDMARKETINGDATE": "",
      "MARKETINGCATEGORYNAME": "EMERGENCY USE AUTHORIZATION",
      "APPLICATIONNUMBER": "",
      "LABELERNAME": "Eli Lilly and Company",
      "SUBSTANCENAME": "BARICITINIB",
      "ACTIVE_NUMERATOR_STRENGTH": 4,
      "ACTIVE_INGRED_UNIT": "mg/1",
      "PHARM_CLASSES": "Janus Kinase Inhibitor [EPC], Janus Kinase Inhibitors [MoA]",
      "DEASCHEDULE": "",
      "NDC_EXCLUDE_FLAG": "N",
      "LISTING_RECORD_CERTIFIED_THROUGH": 20231231
    },
    {
      "PRODUCTID": "0002-6902_619c71c0-de59-4bcf-a98b-cf6b78280395",
      "PRODUCTNDC": "0002-6902",
      "PRODUCTTYPENAME": "HUMAN PRESCRIPTION DRUG",
      "PROPRIETARYNAME": "JAYPIRCA",
      "PROPRIETARYNAMESUFFIX": "",
      "NONPROPRIETARYNAME": "pirtobrutinib",
      "DOSAGEFORMNAME": "TABLET, COATED",
      "ROUTENAME": "ORAL",
      "STARTMARKETINGDATE": 20230127,
      "ENDMARKETINGDATE": "",
      "MARKETINGCATEGORYNAME": "NDA",
      "APPLICATIONNUMBER": "NDA216059",
      "LABELERNAME": "Eli Lilly and Company",
      "SUBSTANCENAME": "PIRTOBRUTINIB",
      "ACTIVE_NUMERATOR_STRENGTH": 50,
      "ACTIVE_INGRED_UNIT": "mg/1",
      "PHARM_CLASSES": "",
      "DEASCHEDULE": "",
      "NDC_EXCLUDE_FLAG": "N",
      "LISTING_RECORD_CERTIFIED_THROUGH": 20241231
    },
    {
      "PRODUCTID": "0002-7026_619c71c0-de59-4bcf-a98b-cf6b78280395",
      "PRODUCTNDC": "0002-7026",
      "PRODUCTTYPENAME": "HUMAN PRESCRIPTION DRUG",
      "PROPRIETARYNAME": "JAYPIRCA",
      "PROPRIETARYNAMESUFFIX": "",
      "NONPROPRIETARYNAME": "pirtobrutinib",
      "DOSAGEFORMNAME": "TABLET, COATED",
      "ROUTENAME": "ORAL",
      "STARTMARKETINGDATE": 20230127,
      "ENDMARKETINGDATE": "",
      "MARKETINGCATEGORYNAME": "NDA",
      "APPLICATIONNUMBER": "NDA216059",
      "LABELERNAME": "Eli Lilly and Company",
      "SUBSTANCENAME": "PIRTOBRUTINIB",
      "ACTIVE_NUMERATOR_STRENGTH": 100,
      "ACTIVE_INGRED_UNIT": "mg/1",
      "PHARM_CLASSES": "",
      "DEASCHEDULE": "",
      "NDC_EXCLUDE_FLAG": "N",
      "LISTING_RECORD_CERTIFIED_THROUGH": 20241231
    },
    {
      "PRODUCTID": "0002-7510_e57e8ab9-295b-4fb7-b723-e7b008117e9a",
      "PRODUCTNDC": "0002-7510",
      "PRODUCTTYPENAME": "HUMAN PRESCRIPTION DRUG",
      "PROPRIETARYNAME": "Humalog",
      "PROPRIETARYNAMESUFFIX": "",
      "NONPROPRIETARYNAME": "Insulin lispro",
      "DOSAGEFORMNAME": "INJECTION, SOLUTION",
      "ROUTENAME": "INTRAVENOUS; SUBCUTANEOUS",
      "STARTMARKETINGDATE": 19960614,
      "ENDMARKETINGDATE": "",
      "MARKETINGCATEGORYNAME": "BLA",
      "APPLICATIONNUMBER": "BLA020563",
      "LABELERNAME": "Eli Lilly and Company",
      "SUBSTANCENAME": "INSULIN LISPRO",
      "ACTIVE_NUMERATOR_STRENGTH": 100,
      "ACTIVE_INGRED_UNIT": "[iU]/mL",
      "PHARM_CLASSES": "Insulin Analog [EPC], Insulin [Chemical/Ingredient]",
      "DEASCHEDULE": "",
      "NDC_EXCLUDE_FLAG": "N",
      "LISTING_RECORD_CERTIFIED_THROUGH": 20241231
    },
    {
      "PRODUCTID": "0002-7511_2df70c11-9794-423a-97cf-ee6e95f984f8",
      "PRODUCTNDC": "0002-7511",
      "PRODUCTTYPENAME": "HUMAN PRESCRIPTION DRUG",
      "PROPRIETARYNAME": "Humalog",
      "PROPRIETARYNAMESUFFIX": "Mix75/25",
      "NONPROPRIETARYNAME": "Insulin lispro",
      "DOSAGEFORMNAME": "INJECTION, SUSPENSION",
      "ROUTENAME": "SUBCUTANEOUS",
      "STARTMARKETINGDATE": 19991222,
      "ENDMARKETINGDATE": "",
      "MARKETINGCATEGORYNAME": "BLA",
      "APPLICATIONNUMBER": "BLA021017",
      "LABELERNAME": "Eli Lilly and Company",
      "SUBSTANCENAME": "INSULIN LISPRO",
      "ACTIVE_NUMERATOR_STRENGTH": 100,
      "ACTIVE_INGRED_UNIT": "[iU]/mL",
      "PHARM_CLASSES": "Insulin Analog [EPC], Insulin [Chemical/Ingredient]",
      "DEASCHEDULE": "",
      "NDC_EXCLUDE_FLAG": "N",
      "LISTING_RECORD_CERTIFIED_THROUGH": 20241231
    },
    {
      "PRODUCTID": "0002-7512_09eaf686-d387-4573-9231-e7809b29a083",
      "PRODUCTNDC": "0002-7512",
      "PRODUCTTYPENAME": "HUMAN PRESCRIPTION DRUG",
      "PROPRIETARYNAME": "Humalog",
      "PROPRIETARYNAMESUFFIX": "Mix50/50",
      "NONPROPRIETARYNAME": "Insulin lispro",
      "DOSAGEFORMNAME": "INJECTION, SUSPENSION",
      "ROUTENAME": "SUBCUTANEOUS",
      "STARTMARKETINGDATE": 19991222,
      "ENDMARKETINGDATE": 20240331,
      "MARKETINGCATEGORYNAME": "BLA",
      "APPLICATIONNUMBER": "BLA021018",
      "LABELERNAME": "Eli Lilly and Company",
      "SUBSTANCENAME": "INSULIN LISPRO",
      "ACTIVE_NUMERATOR_STRENGTH": 100,
      "ACTIVE_INGRED_UNIT": "[iU]/mL",
      "PHARM_CLASSES": "Insulin Analog [EPC], Insulin [Chemical/Ingredient]",
      "DEASCHEDULE": "",
      "NDC_EXCLUDE_FLAG": "N",
      "LISTING_RECORD_CERTIFIED_THROUGH": ""
    },
    {
      "PRODUCTID": "0002-7516_e57e8ab9-295b-4fb7-b723-e7b008117e9a",
      "PRODUCTNDC": "0002-7516",
      "PRODUCTTYPENAME": "HUMAN PRESCRIPTION DRUG",
      "PROPRIETARYNAME": "Humalog",
      "PROPRIETARYNAMESUFFIX": "",
      "NONPROPRIETARYNAME": "Insulin lispro",
      "DOSAGEFORMNAME": "INJECTION, SOLUTION",
      "ROUTENAME": "INTRAVENOUS; SUBCUTANEOUS",
      "STARTMARKETINGDATE": 19980220,
      "ENDMARKETINGDATE": "",
      "MARKETINGCATEGORYNAME": "BLA",
      "APPLICATIONNUMBER": "BLA020563",
      "LABELERNAME": "Eli Lilly and Company",
      "SUBSTANCENAME": "INSULIN LISPRO",
      "ACTIVE_NUMERATOR_STRENGTH": 100,
      "ACTIVE_INGRED_UNIT": "[iU]/mL",
      "PHARM_CLASSES": "Insulin Analog [EPC], Insulin [Chemical/Ingredient]",
      "DEASCHEDULE": "",
      "NDC_EXCLUDE_FLAG": "N",
      "LISTING_RECORD_CERTIFIED_THROUGH": 20241231
    },
    {
      "PRODUCTID": "0002-7533_e57e8ab9-295b-4fb7-b723-e7b008117e9a",
      "PRODUCTNDC": "0002-7533",
      "PRODUCTTYPENAME": "HUMAN PRESCRIPTION DRUG",
      "PROPRIETARYNAME": "Humalog",
      "PROPRIETARYNAMESUFFIX": "",
      "NONPROPRIETARYNAME": "Insulin lispro",
      "DOSAGEFORMNAME": "INJECTION, SOLUTION",
      "ROUTENAME": "INTRAVENOUS; SUBCUTANEOUS",
      "STARTMARKETINGDATE": 20230802,
      "ENDMARKETINGDATE": "",
      "MARKETINGCATEGORYNAME": "BLA",
      "APPLICATIONNUMBER": "BLA020563",
      "LABELERNAME": "Eli Lilly and Company",
      "SUBSTANCENAME": "INSULIN LISPRO",
      "ACTIVE_NUMERATOR_STRENGTH": 100,
      "ACTIVE_INGRED_UNIT": "[iU]/mL",
      "PHARM_CLASSES": "Insulin Analog [EPC], Insulin [Chemical/Ingredient]",
      "DEASCHEDULE": "",
      "NDC_EXCLUDE_FLAG": "N",
      "LISTING_RECORD_CERTIFIED_THROUGH": 20241231
    },
    {
      "PRODUCTID": "0002-7575_83c555b7-3807-4f0b-8812-63b6082d026c",
      "PRODUCTNDC": "0002-7575",
      "PRODUCTTYPENAME": "HUMAN PRESCRIPTION DRUG",
      "PROPRIETARYNAME": "Omvoh",
      "PROPRIETARYNAMESUFFIX": "",
      "NONPROPRIETARYNAME": "mirikizumab-mrkz",
      "DOSAGEFORMNAME": "INJECTION, SOLUTION",
      "ROUTENAME": "INTRAVENOUS",
      "STARTMARKETINGDATE": 20231026,
      "ENDMARKETINGDATE": "",
      "MARKETINGCATEGORYNAME": "BLA",
      "APPLICATIONNUMBER": "BLA761279",
      "LABELERNAME": "Eli Lilly and Company",
      "SUBSTANCENAME": "MIRIKIZUMAB",
      "ACTIVE_NUMERATOR_STRENGTH": 20,
      "ACTIVE_INGRED_UNIT": "mg/mL",
      "PHARM_CLASSES": "Interleukin-23 Antagonist [EPC], Interleukin-23 Antagonists [MoA]",
      "DEASCHEDULE": "",
      "NDC_EXCLUDE_FLAG": "N",
      "LISTING_RECORD_CERTIFIED_THROUGH": 20241231
    },
    {
      "PRODUCTID": "0002-7589_0a45f258-0828-4a0c-b992-a8ba521b84d0",
      "PRODUCTNDC": "0002-7589",
      "PRODUCTTYPENAME": "HUMAN PRESCRIPTION DRUG",
      "PROPRIETARYNAME": "Bebtelovimab",
      "PROPRIETARYNAMESUFFIX": "",
      "NONPROPRIETARYNAME": "Bebtelovimab",
      "DOSAGEFORMNAME": "INJECTION, SOLUTION",
      "ROUTENAME": "INTRAVENOUS",
      "STARTMARKETINGDATE": 20220211,
      "ENDMARKETINGDATE": "",
      "MARKETINGCATEGORYNAME": "EMERGENCY USE AUTHORIZATION",
      "APPLICATIONNUMBER": "",
      "LABELERNAME": "Eli Lilly and Company",
      "SUBSTANCENAME": "BEBTELOVIMAB",
      "ACTIVE_NUMERATOR_STRENGTH": 87.5,
      "ACTIVE_INGRED_UNIT": "mg/mL",
      "PHARM_CLASSES": "",
      "DEASCHEDULE": "",
      "NDC_EXCLUDE_FLAG": "N",
      "LISTING_RECORD_CERTIFIED_THROUGH": 20241231
    },
    {
      "PRODUCTID": "0002-7597_8008d181-4679-4320-a624-0072056c40c7",
      "PRODUCTNDC": "0002-7597",
      "PRODUCTTYPENAME": "HUMAN PRESCRIPTION DRUG",
      "PROPRIETARYNAME": "ZYPREXA",
      "PROPRIETARYNAMESUFFIX": "Intramuscular",
      "NONPROPRIETARYNAME": "Olanzapine",
      "DOSAGEFORMNAME": "INJECTION, POWDER, FOR SOLUTION",
      "ROUTENAME": "INTRAMUSCULAR",
      "STARTMARKETINGDATE": 20040401,
      "ENDMARKETINGDATE": "",
      "MARKETINGCATEGORYNAME": "NDA",
      "APPLICATIONNUMBER": "NDA021253",
      "LABELERNAME": "Eli Lilly and Company",
      "SUBSTANCENAME": "OLANZAPINE",
      "ACTIVE_NUMERATOR_STRENGTH": 10,
      "ACTIVE_INGRED_UNIT": "mg/2mL",
      "PHARM_CLASSES": "Atypical Antipsychotic [EPC]",
      "DEASCHEDULE": "",
      "NDC_EXCLUDE_FLAG": "N",
      "LISTING_RECORD_CERTIFIED_THROUGH": 20231231
    },
    {
      "PRODUCTID": "0002-7623_3af0bc84-13d6-46aa-a4c0-c62410b73bc6",
      "PRODUCTNDC": "0002-7623",
      "PRODUCTTYPENAME": "HUMAN PRESCRIPTION DRUG",
      "PROPRIETARYNAME": "Alimta",
      "PROPRIETARYNAMESUFFIX": "",
      "NONPROPRIETARYNAME": "Pemetrexed disodium",
      "DOSAGEFORMNAME": "INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION",
      "ROUTENAME": "INTRAVENOUS",
      "STARTMARKETINGDATE": 20040204,
      "ENDMARKETINGDATE": "",
      "MARKETINGCATEGORYNAME": "NDA",
      "APPLICATIONNUMBER": "NDA021462",
      "LABELERNAME": "Eli Lilly and Company",
      "SUBSTANCENAME": "PEMETREXED DISODIUM HEPTAHYDRATE",
      "ACTIVE_NUMERATOR_STRENGTH": 500,
      "ACTIVE_INGRED_UNIT": "mg/20mL",
      "PHARM_CLASSES": "Folate Analog Metabolic Inhibitor [EPC], Folic Acid Metabolism Inhibitors [MoA]",
      "DEASCHEDULE": "",
      "NDC_EXCLUDE_FLAG": "N",
      "LISTING_RECORD_CERTIFIED_THROUGH": 20241231
    },
    {
      "PRODUCTID": "0002-7635_0a5b6cfe-5486-4622-a362-f1afd9bd8f56",
      "PRODUCTNDC": "0002-7635",
      "PRODUCTTYPENAME": "HUMAN PRESCRIPTION DRUG",
      "PROPRIETARYNAME": "ZYPREXA",
      "PROPRIETARYNAMESUFFIX": "Relprevv",
      "NONPROPRIETARYNAME": "Olanzapine pamoate",
      "DOSAGEFORMNAME": "KIT",
      "ROUTENAME": "INTRAMUSCULAR",
      "STARTMARKETINGDATE": 20091211,
      "ENDMARKETINGDATE": "",
      "MARKETINGCATEGORYNAME": "NDA",
      "APPLICATIONNUMBER": "NDA022173",
      "LABELERNAME": "Eli Lilly and Company",
      "SUBSTANCENAME": "",
      "ACTIVE_NUMERATOR_STRENGTH": "",
      "ACTIVE_INGRED_UNIT": "",
      "PHARM_CLASSES": "",
      "DEASCHEDULE": "",
      "NDC_EXCLUDE_FLAG": "N",
      "LISTING_RECORD_CERTIFIED_THROUGH": 20231231
    },
    {
      "PRODUCTID": "0002-7636_0a5b6cfe-5486-4622-a362-f1afd9bd8f56",
      "PRODUCTNDC": "0002-7636",
      "PRODUCTTYPENAME": "HUMAN PRESCRIPTION DRUG",
      "PROPRIETARYNAME": "ZYPREXA",
      "PROPRIETARYNAMESUFFIX": "Relprevv",
      "NONPROPRIETARYNAME": "Olanzapine pamoate",
      "DOSAGEFORMNAME": "KIT",
      "ROUTENAME": "INTRAMUSCULAR",
      "STARTMARKETINGDATE": 20091211,
      "ENDMARKETINGDATE": "",
      "MARKETINGCATEGORYNAME": "NDA",
      "APPLICATIONNUMBER": "NDA022173",
      "LABELERNAME": "Eli Lilly and Company",
      "SUBSTANCENAME": "",
      "ACTIVE_NUMERATOR_STRENGTH": "",
      "ACTIVE_INGRED_UNIT": "",
      "PHARM_CLASSES": "",
      "DEASCHEDULE": "",
      "NDC_EXCLUDE_FLAG": "N",
      "LISTING_RECORD_CERTIFIED_THROUGH": 20231231
    },
    {
      "PRODUCTID": "0002-7637_0a5b6cfe-5486-4622-a362-f1afd9bd8f56",
      "PRODUCTNDC": "0002-7637",
      "PRODUCTTYPENAME": "HUMAN PRESCRIPTION DRUG",
      "PROPRIETARYNAME": "ZYPREXA",
      "PROPRIETARYNAMESUFFIX": "Relprevv",
      "NONPROPRIETARYNAME": "Olanzapine pamoate",
      "DOSAGEFORMNAME": "KIT",
      "ROUTENAME": "INTRAMUSCULAR",
      "STARTMARKETINGDATE": 20091211,
      "ENDMARKETINGDATE": "",
      "MARKETINGCATEGORYNAME": "NDA",
      "APPLICATIONNUMBER": "NDA022173",
      "LABELERNAME": "Eli Lilly and Company",
      "SUBSTANCENAME": "",
      "ACTIVE_NUMERATOR_STRENGTH": "",
      "ACTIVE_INGRED_UNIT": "",
      "PHARM_CLASSES": "",
      "DEASCHEDULE": "",
      "NDC_EXCLUDE_FLAG": "N",
      "LISTING_RECORD_CERTIFIED_THROUGH": 20231231
    },
    {
      "PRODUCTID": "0002-7640_3af0bc84-13d6-46aa-a4c0-c62410b73bc6",
      "PRODUCTNDC": "0002-7640",
      "PRODUCTTYPENAME": "HUMAN PRESCRIPTION DRUG",
      "PROPRIETARYNAME": "Alimta",
      "PROPRIETARYNAMESUFFIX": "",
      "NONPROPRIETARYNAME": "Pemetrexed disodium",
      "DOSAGEFORMNAME": "INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION",
      "ROUTENAME": "INTRAVENOUS",
      "STARTMARKETINGDATE": 20070907,
      "ENDMARKETINGDATE": "",
      "MARKETINGCATEGORYNAME": "NDA",
      "APPLICATIONNUMBER": "NDA021462",
      "LABELERNAME": "Eli Lilly and Company",
      "SUBSTANCENAME": "PEMETREXED DISODIUM HEPTAHYDRATE",
      "ACTIVE_NUMERATOR_STRENGTH": 100,
      "ACTIVE_INGRED_UNIT": "mg/4mL",
      "PHARM_CLASSES": "Folate Analog Metabolic Inhibitor [EPC], Folic Acid Metabolism Inhibitors [MoA]",
      "DEASCHEDULE": "",
      "NDC_EXCLUDE_FLAG": "N",
      "LISTING_RECORD_CERTIFIED_THROUGH": 20241231
    },
    {
      "PRODUCTID": "0002-7669_5bdad737-d958-4e6d-ba05-5b3cd39b16af",
      "PRODUCTNDC": "0002-7669",
      "PRODUCTTYPENAME": "HUMAN PRESCRIPTION DRUG",
      "PROPRIETARYNAME": "CYRAMZA",
      "PROPRIETARYNAMESUFFIX": "",
      "NONPROPRIETARYNAME": "ramucirumab",
      "DOSAGEFORMNAME": "SOLUTION",
      "ROUTENAME": "INTRAVENOUS",
      "STARTMARKETINGDATE": 20140421,
      "ENDMARKETINGDATE": "",
      "MARKETINGCATEGORYNAME": "BLA",
      "APPLICATIONNUMBER": "BLA125477",
      "LABELERNAME": "Eli Lilly and Company",
      "SUBSTANCENAME": "RAMUCIRUMAB",
      "ACTIVE_NUMERATOR_STRENGTH": 10,
      "ACTIVE_INGRED_UNIT": "mg/mL",
      "PHARM_CLASSES": "VEGFR2 Inhibitors [MoA], Vascular Endothelial Growth Factor Receptor 2 Antagonist [EPC]",
      "DEASCHEDULE": "",
      "NDC_EXCLUDE_FLAG": "N",
      "LISTING_RECORD_CERTIFIED_THROUGH": 20231231
    },
    {
      "PRODUCTID": "0002-7678_5bdad737-d958-4e6d-ba05-5b3cd39b16af",
      "PRODUCTNDC": "0002-7678",
      "PRODUCTTYPENAME": "HUMAN PRESCRIPTION DRUG",
      "PROPRIETARYNAME": "CYRAMZA",
      "PROPRIETARYNAMESUFFIX": "",
      "NONPROPRIETARYNAME": "ramucirumab",
      "DOSAGEFORMNAME": "SOLUTION",
      "ROUTENAME": "INTRAVENOUS",
      "STARTMARKETINGDATE": 20140421,
      "ENDMARKETINGDATE": "",
      "MARKETINGCATEGORYNAME": "BLA",
      "APPLICATIONNUMBER": "BLA125477",
      "LABELERNAME": "Eli Lilly and Company",
      "SUBSTANCENAME": "RAMUCIRUMAB",
      "ACTIVE_NUMERATOR_STRENGTH": 10,
      "ACTIVE_INGRED_UNIT": "mg/mL",
      "PHARM_CLASSES": "VEGFR2 Inhibitors [MoA], Vascular Endothelial Growth Factor Receptor 2 Antagonist [EPC]",
      "DEASCHEDULE": "",
      "NDC_EXCLUDE_FLAG": "N",
      "LISTING_RECORD_CERTIFIED_THROUGH": 20231231
    },
    {
      "PRODUCTID": "0002-7712_e57e8ab9-295b-4fb7-b723-e7b008117e9a",
      "PRODUCTNDC": "0002-7712",
      "PRODUCTTYPENAME": "HUMAN PRESCRIPTION DRUG",
      "PROPRIETARYNAME": "Humalog",
      "PROPRIETARYNAMESUFFIX": "KwikPen",
      "NONPROPRIETARYNAME": "Insulin lispro",
      "DOSAGEFORMNAME": "INJECTION, SOLUTION",
      "ROUTENAME": "SUBCUTANEOUS",
      "STARTMARKETINGDATE": 20150526,
      "ENDMARKETINGDATE": "",
      "MARKETINGCATEGORYNAME": "BLA",
      "APPLICATIONNUMBER": "BLA205747",
      "LABELERNAME": "Eli Lilly and Company",
      "SUBSTANCENAME": "INSULIN LISPRO",
      "ACTIVE_NUMERATOR_STRENGTH": 200,
      "ACTIVE_INGRED_UNIT": "[iU]/mL",
      "PHARM_CLASSES": "Insulin Analog [EPC], Insulin [Chemical/Ingredient]",
      "DEASCHEDULE": "",
      "NDC_EXCLUDE_FLAG": "N",
      "LISTING_RECORD_CERTIFIED_THROUGH": 20241231
    },
    {
      "PRODUCTID": "0002-7714_e57e8ab9-295b-4fb7-b723-e7b008117e9a",
      "PRODUCTNDC": "0002-7714",
      "PRODUCTTYPENAME": "HUMAN PRESCRIPTION DRUG",
      "PROPRIETARYNAME": "Humalog",
      "PROPRIETARYNAMESUFFIX": "Junior KwikPen",
      "NONPROPRIETARYNAME": "Insulin lispro",
      "DOSAGEFORMNAME": "INJECTION, SOLUTION",
      "ROUTENAME": "SUBCUTANEOUS",
      "STARTMARKETINGDATE": 20170606,
      "ENDMARKETINGDATE": "",
      "MARKETINGCATEGORYNAME": "BLA",
      "APPLICATIONNUMBER": "BLA020563",
      "LABELERNAME": "Eli Lilly and Company",
      "SUBSTANCENAME": "INSULIN LISPRO",
      "ACTIVE_NUMERATOR_STRENGTH": 100,
      "ACTIVE_INGRED_UNIT": "[iU]/mL",
      "PHARM_CLASSES": "Insulin Analog [EPC], Insulin [Chemical/Ingredient]",
      "DEASCHEDULE": "",
      "NDC_EXCLUDE_FLAG": "N",
      "LISTING_RECORD_CERTIFIED_THROUGH": 20241231
    },
    {
      "PRODUCTID": "0002-7715_56a3dd7f-8eaf-4904-9ea3-94e698eec04b",
      "PRODUCTNDC": "0002-7715",
      "PRODUCTTYPENAME": "HUMAN PRESCRIPTION DRUG",
      "PROPRIETARYNAME": "BASAGLAR",
      "PROPRIETARYNAMESUFFIX": "KwikPen",
      "NONPROPRIETARYNAME": "Insulin glargine",
      "DOSAGEFORMNAME": "INJECTION, SOLUTION",
      "ROUTENAME": "SUBCUTANEOUS",
      "STARTMARKETINGDATE": 20151216,
      "ENDMARKETINGDATE": "",
      "MARKETINGCATEGORYNAME": "BLA",
      "APPLICATIONNUMBER": "BLA205692",
      "LABELERNAME": "Eli Lilly and Company",
      "SUBSTANCENAME": "INSULIN GLARGINE",
      "ACTIVE_NUMERATOR_STRENGTH": 100,
      "ACTIVE_INGRED_UNIT": "[iU]/mL",
      "PHARM_CLASSES": "Insulin Analog [EPC], Insulin [CS]",
      "DEASCHEDULE": "",
      "NDC_EXCLUDE_FLAG": "N",
      "LISTING_RECORD_CERTIFIED_THROUGH": 20241231
    },
    {
      "PRODUCTID": "0002-7716_62de9272-71de-4b81-8ccf-ad7806f02081",
      "PRODUCTNDC": "0002-7716",
      "PRODUCTTYPENAME": "HUMAN PRESCRIPTION DRUG",
      "PROPRIETARYNAME": "Portrazza",
      "PROPRIETARYNAMESUFFIX": "",
      "NONPROPRIETARYNAME": "necitumumab",
      "DOSAGEFORMNAME": "SOLUTION",
      "ROUTENAME": "INTRAVENOUS",
      "STARTMARKETINGDATE": 20151124,
      "ENDMARKETINGDATE": "",
      "MARKETINGCATEGORYNAME": "BLA",
      "APPLICATIONNUMBER": "BLA125547",
      "LABELERNAME": "Eli Lilly and Company",
      "SUBSTANCENAME": "NECITUMUMAB",
      "ACTIVE_NUMERATOR_STRENGTH": 16,
      "ACTIVE_INGRED_UNIT": "mg/mL",
      "PHARM_CLASSES": "Epidermal Growth Factor Receptor Antagonist [EPC], HER1 Antagonists [MoA]",
      "DEASCHEDULE": "",
      "NDC_EXCLUDE_FLAG": "N",
      "LISTING_RECORD_CERTIFIED_THROUGH": 20231231
    },
    {
      "PRODUCTID": "0002-7724_39e9a0c8-fced-467c-a773-4c07d7ba060c",
      "PRODUCTNDC": "0002-7724",
      "PRODUCTTYPENAME": "HUMAN PRESCRIPTION DRUG",
      "PROPRIETARYNAME": "TALTZ",
      "PROPRIETARYNAMESUFFIX": "",
      "NONPROPRIETARYNAME": "ixekizumab",
      "DOSAGEFORMNAME": "INJECTION, SOLUTION",
      "ROUTENAME": "SUBCUTANEOUS",
      "STARTMARKETINGDATE": 20160322,
      "ENDMARKETINGDATE": "",
      "MARKETINGCATEGORYNAME": "BLA",
      "APPLICATIONNUMBER": "BLA125521",
      "LABELERNAME": "Eli Lilly and Company",
      "SUBSTANCENAME": "IXEKIZUMAB",
      "ACTIVE_NUMERATOR_STRENGTH": 80,
      "ACTIVE_INGRED_UNIT": "mg/mL",
      "PHARM_CLASSES": "Interleukin-17A Antagonist [EPC], Interleukin-17A Antagonists [MoA]",
      "DEASCHEDULE": "",
      "NDC_EXCLUDE_FLAG": "N",
      "LISTING_RECORD_CERTIFIED_THROUGH": 20231231
    },
    {
      "PRODUCTID": "0002-7728_6f84ba56-a2a5-440e-9d3f-334655934a53",
      "PRODUCTNDC": "0002-7728",
      "PRODUCTTYPENAME": "HUMAN PRESCRIPTION DRUG",
      "PROPRIETARYNAME": "LYUMJEV",
      "PROPRIETARYNAMESUFFIX": "",
      "NONPROPRIETARYNAME": "Insulin lispro-aabc",
      "DOSAGEFORMNAME": "INJECTION, SOLUTION",
      "ROUTENAME": "INTRAVENOUS; SUBCUTANEOUS",
      "STARTMARKETINGDATE": 20200615,
      "ENDMARKETINGDATE": "",
      "MARKETINGCATEGORYNAME": "BLA",
      "APPLICATIONNUMBER": "BLA761109",
      "LABELERNAME": "Eli Lilly and Company",
      "SUBSTANCENAME": "INSULIN LISPRO",
      "ACTIVE_NUMERATOR_STRENGTH": 100,
      "ACTIVE_INGRED_UNIT": "[iU]/mL",
      "PHARM_CLASSES": "Insulin Analog [EPC], Insulin [Chemical/Ingredient]",
      "DEASCHEDULE": "",
      "NDC_EXCLUDE_FLAG": "N",
      "LISTING_RECORD_CERTIFIED_THROUGH": 20241231
    },
    {
      "PRODUCTID": "0002-7737_eee13147-cd23-4ee6-876e-8267fa954b0e",
      "PRODUCTNDC": "0002-7737",
      "PRODUCTTYPENAME": "HUMAN PRESCRIPTION DRUG",
      "PROPRIETARYNAME": "Insulin Lispro",
      "PROPRIETARYNAMESUFFIX": "",
      "NONPROPRIETARYNAME": "Insulin lispro",
      "DOSAGEFORMNAME": "INJECTION, SOLUTION",
      "ROUTENAME": "INTRAVENOUS; SUBCUTANEOUS",
      "STARTMARKETINGDATE": 20200212,
      "ENDMARKETINGDATE": "",
      "MARKETINGCATEGORYNAME": "BLA",
      "APPLICATIONNUMBER": "BLA020563",
      "LABELERNAME": "Eli Lilly and Company",
      "SUBSTANCENAME": "INSULIN LISPRO",
      "ACTIVE_NUMERATOR_STRENGTH": 100,
      "ACTIVE_INGRED_UNIT": "[iU]/mL",
      "PHARM_CLASSES": "Insulin Analog [EPC], Insulin [Chemical/Ingredient]",
      "DEASCHEDULE": "",
      "NDC_EXCLUDE_FLAG": "N",
      "LISTING_RECORD_CERTIFIED_THROUGH": 20241231
    },
    {
      "PRODUCTID": "0002-7752_eee13147-cd23-4ee6-876e-8267fa954b0e",
      "PRODUCTNDC": "0002-7752",
      "PRODUCTTYPENAME": "HUMAN PRESCRIPTION DRUG",
      "PROPRIETARYNAME": "Insulin Lispro",
      "PROPRIETARYNAMESUFFIX": "Junior KwikPen",
      "NONPROPRIETARYNAME": "Insulin lispro",
      "DOSAGEFORMNAME": "INJECTION, SOLUTION",
      "ROUTENAME": "SUBCUTANEOUS",
      "STARTMARKETINGDATE": 20200212,
      "ENDMARKETINGDATE": "",
      "MARKETINGCATEGORYNAME": "BLA",
      "APPLICATIONNUMBER": "BLA020563",
      "LABELERNAME": "Eli Lilly and Company",
      "SUBSTANCENAME": "INSULIN LISPRO",
      "ACTIVE_NUMERATOR_STRENGTH": 100,
      "ACTIVE_INGRED_UNIT": "[iU]/mL",
      "PHARM_CLASSES": "Insulin Analog [EPC], Insulin [Chemical/Ingredient]",
      "DEASCHEDULE": "",
      "NDC_EXCLUDE_FLAG": "N",
      "LISTING_RECORD_CERTIFIED_THROUGH": 20241231
    },
    {
      "PRODUCTID": "0002-7910_8aa4f3ff-a512-4826-b910-85ab6e89f466",
      "PRODUCTNDC": "0002-7910",
      "PRODUCTTYPENAME": "HUMAN PRESCRIPTION DRUG",
      "PROPRIETARYNAME": "Bamlanivimab",
      "PROPRIETARYNAMESUFFIX": "",
      "NONPROPRIETARYNAME": "Bamlanivimab",
      "DOSAGEFORMNAME": "INJECTION, SOLUTION",
      "ROUTENAME": "INTRAVENOUS",
      "STARTMARKETINGDATE": 20201109,
      "ENDMARKETINGDATE": "",
      "MARKETINGCATEGORYNAME": "EMERGENCY USE AUTHORIZATION",
      "APPLICATIONNUMBER": "",
      "LABELERNAME": "Eli Lilly and Company",
      "SUBSTANCENAME": "BAMLANIVIMAB",
      "ACTIVE_NUMERATOR_STRENGTH": 35,
      "ACTIVE_INGRED_UNIT": "mg/mL",
      "PHARM_CLASSES": "",
      "DEASCHEDULE": "",
      "NDC_EXCLUDE_FLAG": "N",
      "LISTING_RECORD_CERTIFIED_THROUGH": 20231231
    },
    {
      "PRODUCTID": "0002-7950_26bc28c0-e8ff-470f-96c7-db44b1e690ab",
      "PRODUCTNDC": "0002-7950",
      "PRODUCTTYPENAME": "HUMAN PRESCRIPTION DRUG",
      "PROPRIETARYNAME": "Etesevimab",
      "PROPRIETARYNAMESUFFIX": "",
      "NONPROPRIETARYNAME": "Etesevimab",
      "DOSAGEFORMNAME": "INJECTION, SOLUTION",
      "ROUTENAME": "INTRAVENOUS",
      "STARTMARKETINGDATE": 20210209,
      "ENDMARKETINGDATE": "",
      "MARKETINGCATEGORYNAME": "EMERGENCY USE AUTHORIZATION",
      "APPLICATIONNUMBER": "",
      "LABELERNAME": "Eli Lilly and Company",
      "SUBSTANCENAME": "ETESEVIMAB",
      "ACTIVE_NUMERATOR_STRENGTH": 35,
      "ACTIVE_INGRED_UNIT": "mg/mL",
      "PHARM_CLASSES": "",
      "DEASCHEDULE": "",
      "NDC_EXCLUDE_FLAG": "N",
      "LISTING_RECORD_CERTIFIED_THROUGH": 20231231
    },
    {
      "PRODUCTID": "0002-8011_83c555b7-3807-4f0b-8812-63b6082d026c",
      "PRODUCTNDC": "0002-8011",
      "PRODUCTTYPENAME": "HUMAN PRESCRIPTION DRUG",
      "PROPRIETARYNAME": "Omvoh",
      "PROPRIETARYNAMESUFFIX": "",
      "NONPROPRIETARYNAME": "mirikizumab-mrkz",
      "DOSAGEFORMNAME": "INJECTION, SOLUTION",
      "ROUTENAME": "SUBCUTANEOUS",
      "STARTMARKETINGDATE": 20231026,
      "ENDMARKETINGDATE": "",
      "MARKETINGCATEGORYNAME": "BLA",
      "APPLICATIONNUMBER": "BLA761279",
      "LABELERNAME": "Eli Lilly and Company",
      "SUBSTANCENAME": "MIRIKIZUMAB",
      "ACTIVE_NUMERATOR_STRENGTH": 100,
      "ACTIVE_INGRED_UNIT": "mg/mL",
      "PHARM_CLASSES": "Interleukin-23 Antagonist [EPC], Interleukin-23 Antagonists [MoA]",
      "DEASCHEDULE": "",
      "NDC_EXCLUDE_FLAG": "N",
      "LISTING_RECORD_CERTIFIED_THROUGH": 20241231
    },
    {
      "PRODUCTID": "0002-8031_024e1f7b-37ec-406c-9cec-bfe491866399",
      "PRODUCTNDC": "0002-8031",
      "PRODUCTTYPENAME": "HUMAN PRESCRIPTION DRUG",
      "PROPRIETARYNAME": "Glucagon",
      "PROPRIETARYNAMESUFFIX": "",
      "NONPROPRIETARYNAME": "glucagon",
      "DOSAGEFORMNAME": "KIT",
      "ROUTENAME": "",
      "STARTMARKETINGDATE": 19990301,
      "ENDMARKETINGDATE": "",
      "MARKETINGCATEGORYNAME": "NDA",
      "APPLICATIONNUMBER": "NDA020928",
      "LABELERNAME": "Eli Lilly and Company",
      "SUBSTANCENAME": "",
      "ACTIVE_NUMERATOR_STRENGTH": "",
      "ACTIVE_INGRED_UNIT": "",
      "PHARM_CLASSES": "",
      "DEASCHEDULE": "",
      "NDC_EXCLUDE_FLAG": "N",
      "LISTING_RECORD_CERTIFIED_THROUGH": 20241231
    }
  ]
}
